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MECHANISMS UNDERLYING DISTINCT EGFR VERSUS FGFR-3 AND
-1 DEPENDENCY IN HUMAN BLADDER CANCER CELLS

Tiewei Cheng, M.D.
Supervisory Professor: David J. McConkey, Ph.D.
The epidermal growth factor receptor (EGFR) and fibroblast growth factor
receptor (FGFR) are activated by gene amplification, mutation and
overexpression in bladder cancer, which drives tumor development and
progression. Both EGFR and FGFR inhibitors are currently being tested in
clinical trials. However, bladder cancer (BC) cells show remarkably
heterogeneous sensitivities to both inhibitors, and the molecular
determinants of this heterogeneity are presently unclear. Therefore, in this
study, using selective EGFR and FGFR inhibitors in BC cells, we
demonstrated that FGFR3 and FGFR1 play largely non-overlapping roles
in mediating proliferation and invasion in the distinct “epithelial” and
“mesenchymal” subsets of human BC cells. Furthermore, we examined
the sensitivities to FGFR3 and EGFR inhibition in a panel of human BC
cells, and found that FGFR3 and EGFR dependency are mutually
exclusive biological phenotypes controlled by PPARγ-FABP4 pathway.
This study significantly extends and complements our knowledge of
molecular mechanism that mediates growth receptor dependent
proliferation in BC.
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CHAPTER 1. INTRODUCTION

1

1.1. Fibroblast growth factor family and its receptors in cancer
1.1.1. The FGF-FGFR signaling system
FGFs. The fibroblast growth factor (FGF) family is composed of 18 ligands
that bind to four homologous high-affinity fibroblast growth factor receptors
(FGFR1-4) [1]. The ligands can be classified into 6 subfamilies based on
sequence similarity: FGF1-2; FGF3, FGF7, FGF10 and FGF22; FGF4-6;
FGF8, FGF17 and FGF18; FGF9, FGF16 and FGF20; and FGF19, FGF21
and FGF23 [1]. There are also 4 “FGFs” that are numbered (FGF11FGF14) but are not assigned to any subfamilies. Although these ligands
share similar amino acid sequence with the FGF family, they do not
activate FGFRs and therefore are not generally grouped into the FGF
family [2]. Typically, FGFs can be classified as intracrine, paracrine and
endocrine ligands respectively. Intracrine FGFs are intracellular molecules
independent of FGFR and they mediate the function of voltage gated
sodium channels [3]. However, paracrine FGFs, which is the major type of
ligand, regulates physiological and pathophysiological functions by binding
with and activating FGFRs at cell surface [4]. Recently, FGF19, FGF21
and FGF23 have been shown to function via endocrine route and are
thought to medicate biological response via FGFRs. These ligands
function over long distances, and are dependent on co-existence of klotho,
a nuclear receptor binds to FGFRs to increase its binding affinity to
specific endocrine FGFs, which then regulate vitamin D, bile acid,
cholesterol, and glucose homeostasis [5].
2

FGFRs. The FGF ligands function by binding to the FGFR family and
activating it through an HSGAG dependent manner. So far, four receptors
(FGFR1, FGFR2, FGFR3 and FGFR4) have been identified in this family.
FGFRs are comprised of three extracellular immunoglobulin domains (D1,
D2, D3), a single-pass trans-membrane domain and a cytoplasmic
tyrosine kinase domain (Figure 1.1) [6]. A distinct character of FGFRs is
the presence of an acidic, serine-rich sequence between D1 and D2
domains, named the acid box. The D2 and D3 domains of FGFRs are
required for ligand binding and are used to determine ligand specificity.
However, the D1 domain and the acidic box are believed to play a vital
role in receptor auto-inhibition. There are several FGFR isoforms
generated by multiple mechanisms, and alternative exon splicing of the D3
domain is the most important one. For instance, alternative splicing at the
second half of the FGFR1-3’s D3 domain produces b and c (i.e. FGFR1b
and FGFR1c) isoforms that carry out discrete FGF binding specificities
(Figure 1.1) [7]. Specifically, b isoforms are generally produced in
epithelial tissue while c isoforms are generated in mesenchymal tissue [8].
Therefore, the FGF family ligand-receptor binding specificity (Table 1.1) is
partially mediated through the primary sequence differences among the 18
FGFs and 7 FGFR isoforms that are produced by alternative splicing. The
ligand-receptor binding specificity is also

3

Figure 1.1 FGFR structure and alternative splicing. a. The basic
structure of the fibroblast growth factor (FGF) –FGF receptor (FGFR)
complex comprises two receptor molecules, two FGFs and one heparan
sulphate proteoglycan (HSPG) chain. b. Ligand-binding specificity is
generated by alternative splicing of the Ig III domain. The first half of Ig III
is encoded by an invariant exon (IIIa), which is spliced to either exon IIIb
or IIIc, both of which splice to the exon that encodes the transmembrane
(TM) region. Adapted from Turner N, Grose R, Nat Rev Cancer. 2010
Feb;10(2):116-29 with the permission from Nature Publishing Group.
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Table 1.1 FGF-FGFR binding specificity.

5

regulated by temporal and spatial expression patterns of FGFs, FGFRs
and HSGAGs.
HSGAG binding and FGF-FGFR dimerization and activation. A
functional FGF-FGFR complex is comprised of two FGF-FGFR-HSGAG
(on a 1:1:1 basis) symmetrical units [9]. HSGAG binds to a basic canyon
at the distal end of the membrane to facilitate and bolster protein to protein
interactions. Ligands, shuttled by FGF-binding protein that releases FGFs
from the extracellular matrix [10], bind to both receptors, and the two
receptors interact with each other through a subdomain at the base of D2
[11]. HSGAG binding serves two primary purposes to promote the FGFR
signaling. First, HSGAG promotes ligand-receptor dimerization by
facilitating and strengthening protein-to-protein interaction between FGF
and FGFR both inside and outside the complex through simultaneously
binding to both ligand and receptor. Second, HSGAG binding to ligands
stabilizes FGFs against degradation, and serves as a storage for ligands
which also control the rate of ligand diffusion [12].
Downstream signaling and its negative regulation. Ligand dependent
dimerization results in a structural shift in the FGFR receptor to activate
the intracellular kinase domain that leads to an intermolecular transphosphorylation of the tyrosine kinase domains of the receptor. The
phosphorylated tyrosine residues serve as docking site for the adaptor
proteins [13], such as FGFR substrate 2 (FRS2), which are
phosphorylated by FGFRs, resulting in the activation of multiple signaling
6

pathways. Among all of the adaptor proteins, FRS2 is the primary adaptor
highly unique to FGFR signaling instead of other growth factor receptors.
FRS2 binds to the intracellular domain of FGFRs using its
phosphorylation-binding domain (PTB), and is then phosphorylated by the
activated FGFRs. The activated FRS2 recruits its own adaptor proteins,
SOS) and GRB2 to activate the downstream signaling pathway [13]. In
addition, GRB2 associated binding protein 1 acts downstream of FGFR
separately from FRS2 to activate an PI3K/AKT-dependent pathway [14].
Independent of FRS2 binding, a separate site in the intracellular portion of
the activated FGFR binds to the SH2 domain of phospholipase Cγ (PLCγ).
The activation of PLCγ facilitates protein kinase C (PKC) signaling [15,16],
which partially augments the activation of MAPK pathway (Figure 1.2).
Following activation of FGFR signaling, signal attenuation and negative
pathway feedback control could take places. First, FGFRs are internalized
and then degraded, which is partially mediated by CBL-mediated monoubiquitylation [17]. Second, MAPK phosphatases such as MAPK
phosphatase 3 and others phosphatases from Sprouty and SEF family are
activated followed by FGFR activation to reduce the level of downstream
signaling [18-21]. These proteins modulate the MAPK signal transduction
cascade at multiple points [22].

7

Figure 1.2 FGFR signaling network. The signal transduction network
downstream of fibroblast growth factor (FGF) receptors (FGFRs), along
with negative regulators. Following ligand binding and receptor
dimerization, the kinase domains transphosphorylate each other, leading
to the docking of adaptor proteins and the activation of four key
downstream pathways: RAS–RAF–MAPK, PI3K–AKT, signal transducer
and activator of transcription (STAT) and phospholipase Cγ (PLCγ)
(green). Signaling can be negatively regulated at several levels by
receptor internalization or the induction of negative regulators, including
8

FGFR-like 1 (FGFRL1), SEF, Sprouty (SPRY), CBL, MAPK phosphatase
1 (MKP1) and MKP3 (brown). Reprinted from Turner N, Grose R, Nat Rev
Cancer. 2010 Feb;10(2):116-29 with the permission from Nature
Publishing Group.
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Physiological function of FGF-FGFR signaling. FGF-FGFR signaling
plays a vitally essential role in embryonic development, wound healing,
and tissue cross-talk.
Several of the 18 FGFs expressed in human cells are vital for embryonic
development due to their essential roles in stimulating cell growth and
migration. Specifically, extensive studies in mouse genetic models and
human pathologies have indicated a pivotal role of FGFs in embryology
from gastrulation to organogenesis [13,23,24]. For instance, FGF8
knockout mice display defects in gastrulation [25], and FGF9 and FGF10
knockout mice die at birth due to their inabilities to develop functional
lungs [26,27]. In humans, FGF3 and FGF10 are associated with hereditary
aplastic syndromes [28,29]; FGF20 is involved in Parkinson’s disease
[30,31]. In addition, defects of FGFRs mostly cause skeletal and growth
defects in mouse models [32,33].
FGF-FGFR signaling also functions in wound healing and tissue repair in
adults. In the process of wound healing, several FGFs, including FGF1, 2,
7 and 10, are released from the extracellular matrix to stimulate
proliferation and migration in both mesenchyme and epithelium to
accomplish wound closure and re-epithelialization [34,35]. FGF2 also has
been shown to stimulate neovascularization, which is an essential
component of the overall wound healing [36]. In parallel, endothelial cells
express the IIIc isoforms of FGFR2 and FGFR3 in response to FGFs

10

stimulation [37].In addition, previous studies have shown the involvement
of FGF16 and FGF18 in angiogenesis in cardiac tissue [38].
The cellular process of epithelial-mesenchymal tissue cross-talk plays an
essential role in both embryonic development and wound healing. The
interaction between these two tissue types is achieved by tissue specific
FGFR variants generated by alternative splicing corresponding to FGFs
produced in the respective tissue microenvironment [39,40]. As a result,
the IIIb isoform of FGFR2 is predominately expressed in epithelia,
whereas the IIIc isoform primarily exists in mesenchyme [8].
1.1.2. Deregulation of FGF-FGFR signaling in cancer
There is substantial evidence that supports the presence of aberrant FGF
signaling in multiple types of malignancies. The underlying mechanisms of
deregulation are manifold and largely tumor specific, but they can be
divided into two groups. One group is genomic FGFR alterations including
activating mutation, FGFR gene amplification and chromosomal
translocation that result in ligand-independent receptor signaling. In
contrast, the other group is alterations that drive ligand dependent
activation including deregulation of autocrine and paracrine signaling and
germline single nucleotide polymorphisms (Figure 1.3).

11

Figure 1.3 Mechanisms of pathogenic cancer cell FGF signalling. The
ways in which fibroblast growth factors (FGFs) and FGF receptors
(FGFRs) can be altered in cancer fall into four main groups. a. Genomic
alteration of FGFR can occur through three mechanisms, leading to
ligand-independent signalling. First, activating mutations can result in
ligand-independent dimerization or constitutive activation of the kinase
(shown by yellow lightning). Second, chromosomal translocations can also
lead to ligand-independent signalling. Intragenic translocations generate
fusion proteins, usually with the amino terminus of a transcription factor
fused to the carboxy-terminal FGFR kinase domain, resulting in
dimerization of the fusion protein and constitutive signalling. b.
Establishment of a paracrine loop. Altered FGFR expression on a cancer
cell can potentially occur by splicing, which alters FGFR specificity, or by
amplification of an FGFR gene to express FGFR out of context, which is
12

activated by FGF (green) expressed by a stromal component. Tumour
cells can stimulate stromal cells to release FGF ligands and increase the
release of ligands from the extracellular matrix. c. Establishment of an
autocrine loop. FGF ligands are produced in an autocrine fashion by a
cancer cell (brown). The autocrine loop can be established by FGFR
expression out of context or by the increased expression of FGF ligands.
d. FGF stromal effects, including angiogenesis. FGF released from
stromal cells or cancer cells can act on endothelial cells to promote
angiogenesis. Reprinted from Turner N, Grose R, Nat Rev Cancer. 2010
Feb;10(2):116-29 with the permission from Nature Publishing Group.
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Activating mutations. A profile of kinase gene mutation status from 210
different human cancers highlights the importance of FGFR mutation in
tumor pathogenesis [41]. Substantial evidence suggests that FGFR
mutations are most frequently associated with the development of
urothelial cancer [42], although this type of mutation is identified in other
types of cancers including multiple myeloma, prostate cancer and cervical
cancer [43,44]. In addition, ~60% of urothelial cancers overall have
somatic mutations in the FGFR3 coding region, and mutations are
predominantly associated with non-muscle invasive urothelial cancers,
whereas only 10-15% of muscle invasive urothelial cancers carry FGFR3
mutations [45]. The most common FGFR3 mutation (>50%) occurs in the
extracellular domain named S249C, where this point mutation leads to
constitutive receptor dimerization and activation independently of ligands
[46,47]. Mutations also occur in the transmembrane domain such as
S371C, and in the kinase domain such as K652E, but less frequently.
Both mutations lead to constitutive activation of the receptors [48].
Interestingly, recent studies indicated that FGFR3 mutations more
commonly co-exist with PIK3CA mutations in urothelial cancer, whereas
FGFR3 mutations do not co-exist with HRAS mutation [49,50]. In addition,
FGFR2 mutations do not coincide with KRAS mutations in endometrial
cancer [51].
Gene amplifications. In general, amplification of FGFR1 and FGFR2 are
identified more frequently than FGFR3 amplification [52], and FGFR3
14

amplification occurs much less frequently than activating mutation of
FGFR3. FGFR1 amplification has been mostly studies in breast cancer
which occurs at ~10% of all breast cancer cases, largely in estrogen
receptor positive type [53,54]. In addition, amplification of FGFR1 was
observed in ovarian cancer, lung cancer and bladder cancer but to a
lesser extent [55-57]. However, it is still debatable whether higher level of
FGFR1 leading to tumorigenesis by aberrantly responding to paracrine
FGF ligands or by ligand independent activation of the signaling pathway.
In general, FGFR2 amplification was reported in ~10% of gastric cancers
[58,59]. Strong evidence suggests that FGFR2 amplification in gastric
cancer cells results in ligand independent signaling, although paracrine
secretion of FGF7 may partially promote cellular proliferation in vivo [60].
Chromosomal translocations. A good example of FGFR chromosomal
translocation come from the study of multiple myeloma, where 15% of
cancers harbor a t(4:14) translocation that directly connects FGFR3 at
4p16.3 to the immunoglobulin heavy chain IGH locus at 14q32 [61]. The
intergenic translocation with the breakpoints at ~70kb upstream of FGFR3,
renders the FGFR3 gene to be controlled by highly active IGH promoter.
Ultimately, the consequence of the translocation is to cause high level
overexpression of FGFR3, which leads to aberrant ligand dependent or
independent signaling [62]. It is also important to note FGFR3 mutations
exist in a fraction (~5% cases) of the t(4:14) multiple myeloma, which
would possibly further reinforce the FGFR3 signaling [63]. The importance
15

of this t(4:14) translocation in multiple myeloma has been modeled using
transgenic mice [61], and is associated with poor prognosis. Studies also
demonstrated the t(4:14) myeloma cells are highly sensitive to FGFR3
inhibition [64,65]. In addition, several FGFR intragenic translocations have
been discovered, which typically results in a fusion protein comprised of
the N terminus of a transcription factor fused onto an FGFR kinase
domain which leads to constitutive FGFR dimerization and activation [6668].
In urothelial cancer, a recent study identified a new FGFR3-TACC3
translocation, where FGFR3 at 4p16.3 is re-arranged to form a t(4:7)
translocation that results in a FGFR3-BAI1-associated protein 2-like 1
(BAIAP2L1) fusion at RT112, RT4 and SW780 [69]. The fusion receptor
causes high levels of ligand independent activation of FGFR3. Several
other studies have demonstrated that these cells exhibited a high level of
dependency on FGFR3 signaling and were extremely sensitive to FGFR
inhibition [47,49,70], which suggested that this translocation might be the
determinant of FGFR dependency in RT112, RT4 and SW780. It is still
unclear which mechanism causes the activation of FGFR signaling by the
FGFR3-TACC3 fusion protein. However, William et al [69] suggested that
the loss of the C-terminus of the FGFR3 in this translocation was not
sufficient to cause the activation of FGFR signaling, which implicates that
presence of fusion partners in this FGFR3-TACC3 translocation.
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1.2. Epidermal growth factor receptor in cancer
1.2.1. The EGFR signaling system
The epidermal growth factor receptor (EGFR) is a transmembrane
tyrosine kinase receptor of the ErbB family [71,72]. The ErbB family is
consist of four related receptors: EGFR (Erb1/HER1), ErbB2 (HER2/neu),
ErbB3 (HER3), and ErbB4 (HER4) [73,74]. EGFR activation engages
three major downstream signaling pathways including MAPK/Erk pathway,
PI3K/AKT and PKC pathway. These three pathways are cross-connected
at multiple points that lead to signal interaction, integration and ultimately
pathway cascade. As a result, the activation of EGFR in a particular cell
results in a variety of biological consequences [74]. Specifically, receptor
activation recruits and phosphorylates multiple intracellular substrates,
which leads to pathway cascade that engage cellular functions including
cell proliferation, growth and survival, cell migration and invasion,
angiogenesis and tumor metastasis.
EGFR signaling. Similar to FGFR signaling, the EGFR signal cascade is
comprised of three phases that are ligand binding and sub-sequential
receptor dimerization and activation, phosphorylation of cytoplasmic
substrate to initiate intracellular signaling cascade, and finally various
cellular responses driven by diverse gene transcription activities [73].
EGFR is comprised of an extracellular region (ectodomain), a
transmembrane domain, and an intracellular kinase domain with a
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regulatory carboxyl terminal segment [75]. The ectodomain is composed
of two types of sub-domains, namely the L domain and a cysteine-rich
(CR) domain [73], where only the L type of domain is used for ligand
binding. A variety of ErbB family ligands bind to EGFR and drive homo- or
hetero-dimerization with the other three ErbB receptors [76-78]. However,
EGF and transforming growth factor-α (TGFα) are believed to be the most
important ligands for EGFR [79]. Following ligand binding, EGFR
extracellular domains undergo substantial structure re-configuration that
leads to homo- and hetero-dimerization of receptors [77], which activate
the intrinsic EGFR tyrosine kinase domain and sub-sequential
autophosphorylation of the receptor intracellular kinase domain. Followed
by the activation of EGFR tyrosine kinase, multiple intracellular substrates
including SOS and GRB2 are recruited to specific phosphotyrosine sites
on the receptor [80]. There are 3 major downstream signaling pathways
induced by EGFR activation. One of them is Ras/Raf/MAPK pathway. The
activation of Ras by adaptor molecules Grb2/SOS initiates the activation
of mitogen-activated protein kinases (MAPKs) and ERK1/2 through
multiple steps of signal cascade, which in turn regulate transcription
factors linked to cell proliferation and survival [81]. The second signaling
route in EGFR activation is the PI3K/AKT pathway [82,83], which
transduces a signal cascade to trigger cellular responses ranging from cell
proliferation and survival to migration and invasion. The third downstream
signaling is through protein kinase C and Stat. The activation of this route
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initiates distinct transcriptional events that regulate a variety of cellular
responses including cell survival, invasion and DNA repair [73].
1.2.2. Deregulation of EGFR in cancer
Similar to FGFR deregulation in cancer, deregulation of tightly controlled
EGFR signaling drives the development of malignancy (oncogene
addiction) in multiple types of cancer. Among them, non-small cell lung
carcinoma (NSCLC) is the mostly investigated due to its higher
occurrence of EGFR deregulation and relative favorable response to
EGFR targeted therapy compared to other types of cancer.
Several mechanisms of EGFR alteration, including EGFR gene
amplification and activating mutation, overexpression of receptor and
ligands, and/or loss of negative feedback regulation[84], could lead to the
abnormal receptor activation, which ultimately drives the tumor
development and progression. Below we will discuss the two most
extensively studied EGFR alterations: EGFR gene amplification and
activating mutation.
EGFR gene amplification. One of the most investigated EGFR
alternations is activation of EGFR signaling through increased gene copy
number through amplification. EGFR is frequently overexpressed in many
human tumors including breast and lung cancer, head and neck cancer,
urothelial cancer, colorectal cancer, ovarian cancer, prostate cancer, and
glioblastoma [85]. The increased expression can exceed a threshold,
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which results in ligand independent constitutive activation of its tyrosine
kinase and signal cascade that drives EGFR oncogene addiction [74,86].
Elevated EGFR expression is a strong prognostic marker in head and
neck cancer, ovarian cancer and bladder cancer [87]. Specifically, a great
number of studies indicated that the increased EGFR expression highly
correlated with poor clinical outcomes in multiple types of cancer,
including breast, lung, head and neck, and urothelial cancers [88,89].
Furthermore, elevated EGFR gene copy number is associated with
increased clinical response to EGFR TKI erlotinib and mAbs cetuximab in
NSCLC [90].
Activating mutation. EGFR activating mutations were first reported in
NSCLC through retrospective studies of EGFR mutation status in early
clinical trials of gefitinib or erlotinib [91]. It was then discovered that EGFR
activating mutations are strongly predictive of benefit from EGFR targeted
therapy [91] mainly because the gain-of-function mutation drives
continued oncogenic signaling (oncogene addiction). Up to date, there are
two most common mutation types that account for >90% of EGFR
mutations revealed in NSCLC. Mutations in exon 19 that account for 4550% of EGFR mutation incidence result in small in-frame deletions [92].
The second most common mutation locating in exon 21 (activation loop of
EGFR) is a point mutation L858R that comprise about 45% of EGFR
mutation [92]. Overall, the activating mutations cause ligand independent
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activation of EGFR signaling and simultaneously result in EGFR oncogene
addiction.
Additionally, EGFR mutations can be accompanied by gene amplification.
For example, EGFRvIII, a deletion variant that lacks exon 2-7
(extracellular domain), forming a constitutively active receptor was found
predominantly in malignant gliomas (20%-30%), where 50%-60% of
patients bearing the mutation also showed amplification of wild type EGFR
[93]. Follow up studies revealed that EGFRvIII was also expressed in
head and neck cancer, lung cancer and breast cancer, although the
occurrence rate was not as high as it is in malignant gliomas [94].

1.3.

Role of FGFR and EGFR signaling in the development of

bladder Cancer
1.3.1. Bladder cancer stratification and management
Bladder cancer occurs with a very high incidence worldwide. Each year,
~400,000 new cases are diagnosed and ~ 150,000 disease-related deaths
occur [95]. In United States, BC was ranked as the fourth most common
malignancy and eighth most common cancer-related death in men in 2012
[96]. The most frequent histologic type of BCs is urothelial carcinoma
(UC) (~90%), whereas squamous cell carcinoma and adenocarcinoma
combined accounts for <10% of BCs [97]. BCs are diagnosed using the
TNM classification system along with tumor grade, which helps surgical
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and medical oncologist to determine the treatment regimens and to predict
the prognosis. The TNM classification system describes the depth of
tumor penetrating into the bladder tissue (T), the status of regional lymph
node (N) and the presence or absence of distant metastases (M).
Bladder cancer can be separated into two major phenotypic variants:
superficial non-muscle-invasive UCs and muscle invasive UCs [98]. Up to
80% of the BCs are superficial non-muscle-invasive tumors at the time of
diagnosis [97]. These tumors arise from hyperplastic urothelium and tend
to localize within the bladder lining and connective tissues, therefore only
a small portion (~20%) will eventually progress to become invasive
tumors. The non-muscle-invasive BCs are normally managed by
cytoscopic resection with or without intravesical instillation of
immunotherapy agents including bacillus Calmetee-Guerin (BCG) [99].
However, up to ~70% of these tumors recur as non-muscle-invasive
disease, which results in the need for long-term surveillance and frequent
tumor resection and disease management, therefore making BC one of
the most expensive malignancies to manage [99]. On the other side,
~20% of BCs are muscle-invasive tumors at the time of diagnosis [97].
These tumors arise from severe dysplasia or carcinoma in situ (CIS) and
tend to invade into bladder muscle layer and finally metastasize to
regional lymph nodes and distant organs. Therefore, muscle-invasive BCs
are highly lethal. The standard care for muscle invasive BCs is radical
cystectomy, with or without adjuvant or neoadjuvant chemotherapy [99].
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Regardless of recent advance in radical cystectomy, chemo-radiation
therapy, chemotherapy and targeted therapy, 50% of the muscle-invasive
BC patients die after 5 within of diagnosis [99]. Therefore, it is very
important to identify the molecular mechanisms underlying the metastatic
profile of muscle-invasive BC and progressive profile of superficial BC into
muscle invasive phenotype.
1.3.2. Role of FGFR and EGFR signaling in bladder caner
Multiple mechanisms of FGFR activation in bladder cancer have been
identified in recent studies. For example, ~70% of low grade non-muscleinvasive BCs carry FGFR3 mutations which drive ligand independent
activation of FGFR3 [100]. Furthermore, several studies have provided
direct evident to support the cause-effect link between the present of
FGFR3 activating mutations and bladder cancer tumorgenesis [101,102].
Moreover, overexpression of FGFR3 and FGFR1 accounts for ~25% and
15% of this disease respectively [97,103]. Experimental studies have
identified FGFR1 activation as the underlying mechanism that drives cell
proliferation and invasion [103,104]. Overall, FGFR signaling is showed to
mediate cell proliferation, cell migration and invasion and tumor growth
and metastasis in bladder cancer [70,104,105]. Moreover, FGFR inhibitors
showed substantial inhibitory effects against proliferation, invasion and
tumor metastasis in preclinical models both in vivo and in vitro
[70,103,104]. In summary, FGFR signaling is activated in bladder cancer
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to drive tumor development and progression, which provides a rationale
for FGFR targeted therapy in bladder cancer patients.
Similarly, EGFR signaling has long been implicated in bladder cancer
though the molecular mechanism by which EGFR regulates bladder
cancer biology are still not very clearly defined. For example, EGFR
overexpression in bladder cancer is reported by several studies [106,107]
and the overexpression of its ligands in bladder cancer is also revealed by
other studies [108,109] . Overall, EGFR signaling is found to regulate cell
proliferation and tumor growth, cell migration and invasion, and
angiogenesis in bladder cancer [110]. Additionally, the overexpression of
EGFR highly correlates with not only tumor grade and stage [111], but
also patient survival [112]. Furthermore, previous work showed that
transgenic overexpression of EGFR in bladder cancer cells promotes
tumor development and progression in xenograft [113], which directly
supported the role of EGFR in driving tumor biology of bladder cancer.
Moreover, clinically relevant EGFR antagonists and inhibitors showed
significant anti-proliferative and anti-angiogenic effects in preclinical
research [114,115]. In summary, all of the evidence provides direct
rationale to clinically target EGFR in bladder cancer patients.
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1.4. FGFR and EGFR targeted therapy
As discussed above, manifold experimental evidence suggested the role
of deregulated FGFR and EGFR in certain cancers including bladder
cancer, lung cancer, head and neck cancer, colon cancer and multiple
myeloma. Moreover, preclinical studies found significant anti-tumor
activities of FGFR and EGFR antagonists both in vitro and in vivo.
Therefore, investigating clinical utilization of FGFR and EGFR targeted
therapy has become the frontier of translational and clinical research, and
there is high level of enthusiasm to develop promising novel agents for
FGFR and EGFR targeted therapy given the urgent needs to seek better
treatment paradigms to improve patient outcome in clinic.
Although several approaches have been tested to target FGFR and
EGFR, the two most extensively studied and advanced approaches are
monoclonal antibodies [116] (mAbs) directly against the receptors
extracellular region and low-molecular-weight tyrosine kinase inhibitors
(TKIs) [117] that interfere with intracellular tyrosine kinase domain (Figure
1.4). The antibodies bind to the extracellular region of the receptors and
compete with ligands, whereas the TKIs compete intracellularly with ATP
for binding sites at receptor’s tyrosine kinase domain. However, at the
downstream level of signaling pathways, antibodies and TKIs have similar
effects because both of the approaches lead to an effective blockade of
the primary downstream signal transduction including the MAPK pathway
[118], the PI3K/Akt pathway [119], and the PKC/Stat pathway [120]. In
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contrast, there may be two differences between mAbs approach and TKIs
approach. Firstly, mAbs instead of TKIs are able to form a complex
containing receptor that leads to receptor internalization [95], which in turn
cause signal attenuation. Secondly, mAbs but not TKIs also have the
capability to induce antibody-dependent cellular cytotoxicity (ADCC) [96].
Below, we will separately discussed FGFR and EGFR targeted therapy
and their clinical development.
1.4.1. FGFR targeted therapy
Currently, FGFR targeted therapy is still at an early stage of clinical
development where most of the development efforts are focus on antiFGFR TKIs. Two FGFR specific TKIs are being evaluated in clinical trials
despite the fact that multiple other FGFR antagonists have showed antitumor activity in preclinical research [121,122]. One of them is BGJ-398
(Figure 1.5 for structure, Table 1.2 for in vitro IC50) that is developed by
Novartis and is evaluated in advanced solid tumor with FGFR1 or FGFR2
amplification or FGFR3 mutation in phase I clinical trial on does escalation
studies (NCT01004224). Another one is AZD4547 (Figure 1.5 for
structure, Table 1.2 for in vitro IC50), developed by AstraZeneca that just
finished its phase I clinical trial with advanced solid tumors
(NCT01213160). The drug is currently tested in phase II clinical trials in
solid tumors (NCT01795768) as single drug or in combination with
hormonal therapy for breast cancer patients (NCT01202591) or in
combination with
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Figure 1.4 Schematic diagram depicts two approach for targeted therapy.
Left panel, FGFR-specific monoclonal antibodies bind the extracellular
domain of the receptor and inhibit FGFR signaling, causing changes in
tumor cell proliferation and survival.
Right panel, treatment of tumor cells with TKIs such as PD173074 or
TKI258 blocks ligand-induced FGFR activity and constitutive FGFR
signaling from mutated or amplified receptors. FRS2 Tyr phosphorylation
decreases, causing an uncoupling of Grb2 from the adaptor protein and a
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decrease in ERK and AKT activity. Adapted from Nancy E. Hynes et al.,
2010, Cancer Res; 70(13); 5199–202 with the permission from American
Association for Cancer Research.

28

chemotherapy for advanced gastric cancer or NSCLC patients
(NCT01824901, NCT01457846). Regarding the mAb approach, a specific
inhibitory monoclonal antibody targeting FGFR3 was development by
Genentech, R3Mab [64] and is currently tested in preclinical models
[64,123]. The preclinical study results provided direct in vitro and in vivo
proof to support the translation of into clinical trials in patients with either
bladder cancer or hematologic cancer. Overall, the various biological
function of FGFR makes it very attractive therapeutic target, and future
clinical development efforts are needed for proof-of-concept and
developing successful clinical strategies to target FGFR.
1.4.2. EGFR targeted therapy
Compared to FGFR targeted therapy, EGFR targeted therapy has been in
development for years, and there are several successful stories.
Cetuximab [88], a chimaeric anti-EGFR mABs, was approved by the FDA
for treating patients with advanced colon cancer refractory to irinotecan
(CPT-11) in 2004. Other examples are gefitinib (Iressa, ZD1839) (Figure
1.5 for structure, Table 1.2 for in vitro profile of IC50) and erlotinib, antiEGFR TKIs. Gefitinib showed increased patient response rate in nonsmall cell lung cancer (NSCLC) from multiple phase II clinical trials
[124,125], which led to accelerated FDA approval for treatment of
advanced NSCLC refractory to
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Figure 1.5 Structure of BGJ-398 [126], AZD4547 [127] and Gefitinib
[128].
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A. in vitro profile of BGJ-398 and AZD4547
Enzyme IC50 (μM)

Kinase

Cellular IC50 (μM)

BGJ-398

AZD4547

BGJ-398

AZD4547

FGFR1

0.0009

0.0002

0.0029

0.012

FGFR2

0.0014

0.0025

0.0020

0.002

FGFR3

0.0010

0.0018

0.0020

0.040

FGFR4

0.060

0.165

N/A

0.142

VEGFR2

0.18

N/A

1.449

N/A

IGFR

>10

0.581

N/A

0.828

EGFR

>10

>100

N/A

N/A

erbB2

>10

>100

N/A

N/A

erbB3

>10

>100

N/A

N/A

erbB4

>10

>100

N/A

N/A

AKT

>10

>100

N/A

N/A

PI3K

>10

>100

N/A

N/A

*reference: [126,127]

B. in vitro profile of Gefitinib
Kinase

Enzyme IC50 (μM)

EGFR

0.027

erbB2

6.8

Raf

>10

MEK-1

>10

ERK-2

>10

*reference: [128]

Table 1.2 selectivity of BGJ-398, AZD4545 and Gefitinib
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chemotherapy in 2003. Additionally, FDA approved erlotinib for treatment
of metastatic NSCLC patients with EGFR exon 19 deletions or exon 21
substitution mutation in 2013 [129]. However, the follow up studies
revealed that anti-EGFR agents, either mAbs or TKIs failed to improve
survival benefit (overall survival) although tumor regression was
achienved in multiple large clinical trials in NSCLC [130]. These
observations reduced enthusiasm for continuous development of EGFR
targeted therapy, and led to limited FDA approval for EGFR targeted
therapy and restricted use of gefitinib in NSCLC patients. Therefore, it is
of pivotal importance to investigate and discover biomarkers that can lead
the selection of patients who are predicted to benefit from EGFR targeted
therapy.
In bladder cancer, there is continued interest in EGFR targeted therapy.
Specifically, multiple clinical trials that evaluate EGFR targeted therapy
agents in conjunction with conventional chemotherapy underway. For
example, erlotinib is being evaluated in muscle invasive bladder cancer
patients both before and after surgery (NCT00380029). Overall, EGFR still
remains as an attractive target in bladder cancer and future development
efforts should focus on investigating clinical applicable biomarkers to
identify the appropriate subset of patients who can benefit from EGFR
target therapy strategy.
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1.5. Escape mechanism of EGFR and FGFR targeted therapy
Various drugs targeting EGFR, through either mAbs or TKIs, have proven
effective in subsets of patients in several types of cancer. Good examples
are Cetuximab, a chimeric monoclonal antibody that is specific for the
extracellular domain of the receptor, and gefitinib and erlotinib, TKIs
competing with ATP for intracellular binding domain of the receptor, which
have been approved for the treatment of several cancer types [72,84].
However, the majority of patients do not respond to EGFR targeted
therapy and a high rate of acquired resistance to these therapeutic drugs
is observed in patients that do respond [131], suggesting both intrinsic and
acquired mechanisms of resistance. Recently, a number of studies
indicated a secondary mutation of egfr, and activities of other tyrosine
kinase receptor including cMET, IGF-1R and FGFRs as mechanisms for
resistance. Thus, it is necessary to further understand the resistance
mechanisms that help the development of novel strategies to overcome
such resistance.
In contrast, FGFR targeted therapy is still at its early stage of
development. Due to the incidence of FGFRs as oncogenic determinants
in certain types of cancer including bladder cancer, there is a growing
interest in developing selective FGFRs tyrosine kinase inhibitors. A good
example is AZD4547, a pan FGFR1-3 inhibitor, which has recently
entered clinical trials [127]. However, the success of FGFR targeted
therapy will require knowledge of mechanisms of both intrinsic and
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acquired resistance. So far, two individual studies identified the EGFR
activation [132] and a gatekeeper mutation in FGFR3 [133] as two
separate escape mechanisms of FGFRs target therapy and I will present
details below.
1.5.1. Escape mechanisms of FGFR targeted therapy
Secondary V555M gatekeeper mutation of fgfr. Recently, Chell et al
[133] generated a derivative of the KMS-11 myeloma cell line
(FGFR3Y373C, originally sensitive to FGFR inhibition) named KMS-11R by
long-term exposure to an FGFR inhibitor (AZ8010), and showed that the
KMS-11R acquired resistance to AZ8010. The KMS-11R cell line was also
cross-resistant to multiple FGFR TKIs (AZD4547 and PD173074).
Sequencing of FGFR3 in the KMS-11R cells demonstrated the presence
of a heterozygous mutation at the gatekeeper residue, encoding
FGFR3V555M, which restricts the access of FGFR TKIs to the ATP binding
pocket of the FGFR3. That structural change of the FGFR3 intracellular
kinase domain enables this particular cell line to become resistant to
FGFR antagonist. The resistant KMS-11R cells exhibits a constitutive
activation of FGFR signaling regardless of the presence of FGFR TKIs.
Re-activation of EGFR signaling. A recent study by Turner’s group [132]
demonstrated that intrinsic or acquired activation of the EGFR contributes
to the resistance of FGFR TKIs in FGFR3 activated cells. Their study
showed that EGFR signaling was up-regulated following FGFR inhibition
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though impaired EGFR receptor trafficking and the release from negative
feedback in FGFR3 dependent cells, and combining the EGFR TKI with
the FGFR TKI produced synergistic growth inhibition compared to the
effects of inhibiting either receptor alone. These data suggested reactivation of EGFR signaling compensates for the loss of FGFR signaling
that allows the cells to escape from FGFR inhibition. They also
investigated mechanisms for the intrinsic resistance to FGFR inhibition,
and suggested that dominant EGFR signaling in cell lines otherwise
bearing activating FGFR3 mutation which represses the expression of
mutant FGFR3 expression and leads to the intrinsic resistance to FGFR
TKIs.
1.5.2. Resistance mechanisms of EGFR targeted therapy.
Secondary T790M mutation of egfr. The presence of a secondary
mutation of the egfr, which leads to a change from threonine (T) to
methionine (M) at position 790, was first reported in 2005 [134,135]. The
occurrence of the point mutation in tumors that were originally sensitive to
EGFR TKIs led to development of resistance to EGFR TKIs [135].
Structural studies of the intracellular kinase domain of EGFR revealed that
T790M was located in the ATP binding pocket to which EGFR TKIs binds
[136]. It was also demonstrated by structure analysis that the T790M point
mutation results in a higher affinity to ATP and a relative lower affinity to
EGFR TKIs [136]. The T790M mutation presents in approximately 50% of
lung adenocarcinoma tissue as reported in the studies using clinical
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specimens with acquired resistance to EGFR TKIs [137]. In contrast,
tumor cells harboring the T790M mutation only constituted a minority of
the cells before EGFR TKIs treatment. Therefore, the T790M point
mutation was identified as a marker for acquired resistance to EGFR TKIs.
In addition, previous studies indicated that the T790M mutation of egfr
caused increased kinase activity, while exhibiting higher level of tyrosine
phosphorylation as compared to wild-type EGFR, and showing a growth
advantage over wide-type cells [138,139].
MET amplification and HGF overexpression. The MET amplification
was reported in HG827GR, a human lung adenocarcinoma cell line with
acquired resistance to EGFR TKIs, in 2007 [140]. Several studies showed
MET amplification caused the autophosphorylation of MET itself,
heterodimerization with HER3, and activation of the PI3K/Akt pathway in
EGFR TKI resistant cells [140-142]. Thus, the constitutive activation of
PI3K/Akt pathway independent of EGFR activation leads to the failure of
EGFR TKIs, which results in the acquired resistance to EGFR TKIs. The
analysis of clinical lung adenocarcinoma specimens revealed the
incidence of MET amplification is approximately 20% in patients with
acquired resistance [140]. It was also demonstrated that the MET
amplification was independent of T790M point mutation in lung tumors
[141]. In parallel, the overexpression of HGF, the main ligand for the MET
tyrosine kinase receptor, was identified as another mechanism of
resistance to EGFR TKIs [143]. Unlike MET amplification, overexpression
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of HGF stimulates the PI3K/Akt pathway through MET phosphorylation
that is independent of HER3 activation. Furthermore, it was reported that
HGF promotes MET amplification and coexists with T790M mutation in
patients with acquired EGFR TKIs resistance [144]. Together, these
studies suggested that MET/HGF activation is one mechanism of EGFR
resistance.
De-repression of FGFRs. Recently, Ware et al [145] reported that
increased levels of FGFRs mRNA was observed in non-small cell lung
cancer (NSCLC) cells treated with EGFR TKIs, suggesting an activated
FGFR signaling after inhibition of EGFR pathway. They further confirmed
that FGFR induction could result in FGFR signaling through ERK pathway.
The study also demonstrated that either exposure to exogenous FGF2/7
or co-culture of NSCLC cells with human fibroblasts could rescue growth
inhibition induced by EGFR TKIs in NSCLC cells via an FGFR dependent
manner. In a separate study, Thomson et al [146] revealed that NSCLC
cells with a mesenchymal phenotype exhibited remarkable reduction in
sensitivity to EGFR specific monoclonal antibody, and also a decreased
expression and phosphorylation of EGFR. However, these same cells
showed aberrantly escalated FGFR expression and autocrine signaling
that activates the MAPK and PI3K/Akt pathway. Their data suggested that
activated FGFR signaling played a redundant pathway in NSCLC cells
leading to the intrinsic resistant to EGFR monoclonal antibody. Together,
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these results indicated activation of FGFRs tyrosine kinase signaling as
one mechanism of resistance to EGFR inhibition.
1.6. Rationale of the study
It is evident that bladder cancer is one of the leading cancer types with
respect to both occurrence and lethality in the US [96]. Therefore, it is
critical to understand the biology of bladder cancer progression and
metastasis in order to improve the management of the disease with the
ultimate purpose to discover a “cure” for bladder cancer. Given the
potential FGFRs and EGFR addiction that bladder cancer possesses,
which was highlighted by recent publications [103,104,114,115], a great
amount of research focuses on developing strategies to target FGFR and
EGFR in bladder cancer. However, there exist remarkably heterogeneous
responses to both EGFR and FGFR targeted therapy revealed by recent
studies [70,115]. Therefore, it is crucial to understand the molecular
mechanisms that drive such heterogeneity and to identify clinical
biomarkers associated with the subsets patients who can maximally
benefit from FGFR and/or EGFR target therapy. Hence, in this
dissertation, I seek to better understand the role of FGFRs in driving
distinct cell functions proliferation versus invasion, and to dissect the
mechanisms that regulate discretely non-overlapping and mutually
exclusive FGFR and EGFR dependency.
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CHAPTER 2. MATERIALS AND METHODS
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2.1. Chemicals and Reagents
BGJ-398, a novel and selective tyrosine kinase inhibitor (TKI) of FGFR1, 2
and 3, was generously provided by Novartis. Astra Zeneca generously
provided AZD4547, a novel and selective tyrosine kinase inhibitor (TKI) of
FGFR1, 2, and 3 (citation), as well as the EGFR TKI gefitinib (ZD1839,
Iressa®, Astra Zeneca Inc.). For in vitro studies, all three TKIs were
reconstituted in DMSO at a stock concentration of 10 mmol/L, stored at 20°C and diluted in medium just prior to use so that the concentration of
DMSO never exceeded 0.1%. For in vivo studies, TKIs was dissolved in
1% polyoxyethylenesorbitan monooleate (Tween-80) and 99% deionized
water to the desired concentration (12.5 mg/ml).
The antidiabetic drug rosiglitazone, a potent peroxisome proliferator
activated receptor γ (PPARγ) agonist, was purchased from Cayman
Chemical as were the PPARα activator Wy14643, the PPARγ antagonist
GW9662, and the PPARβ antagonist Sulindac. The PPARβ agonist L165,041 was purchased from Sigma-Aldrich. The PPARα antagonist
GW6471 was purchased from Tocris Bioscience. PPAR agonists and
antagonists were stored as stock solutions (100mmol/L in DMSO) at 20°C and diluted to the desired concentrations just before use.
Monoclonal antibodies for FGFR1, FGFR3 and bFGF were purchased
from Cell Signaling. Monoclonal antibodies specific for CHOP, FABP4,
Ki67 and Phospho-FRS2-α (Tyr436) (rabbit) were purchased from Cell
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Signaling; antibodies against ERRFI1 and β-Actin (mouse) were from
Sigma. Horseradish peroxidase-conjugated secondary antibodies were
purchased from Bio-Rad (anti-rabbit) and Promega (anti-mouse).
Small interfering RNA (siRNA) Smartpools for FGFR1, FGFR3, CHOP,
PPARα, β, and γ as well as nonspecific control were purchased from
Dharmacon. Small hairpin RNAs (shRNA) used for stable FGFR1
(V3LHS_634640), bFGF (V3LHS_263179), CHOP (V3LHS_646287) and
FABP4 (V3LHS_407556; V3LHS_407559; V3LHS_353665) knockdown
as well as Precision LentiORFs derived from cDNA coding sequences for
CHOP (PLOHS_100066517) and FGFR3 (PLOHS_100066410)
overexpression were obtained from Open Biosystems.
2.2. Tumor cell lines and culture conditions
Cell lines were obtained from the University of Texas MD Anderson
Cancer Center Bladder SPORE Tissue Bank, and their identities were
confirmed by DNA fingerprinting using the AmpFlSTR® Identifiler®
Amplification (Applied Biosystems) or AmpFlSTR® Profiler® PCR
Amplification (Applied Biosystems) protocols. All cell lines were
maintained as monolayers in modified Eagle’s MEM supplemented with
10% fetal bovine serum, 1% vitamin solution (Mediatech), and 0.5% each
of sodium pyruvate, L-glutamine (Life Technologies),
penicillin/streptomycin solution, and nonessential amino acids
(BioWhittaker) at 37°C in a 5% CO2 incubator.
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2.3. MTT assays
Cells (5×103) were plated in 96-well plates and allowed to adhere for 24
hours before they were incubated with or without increasing
concentrations of BGJ-398 for 48 h or 5 days. MTT (3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays were used
to measure relative cell numbers based on conversion of MTT to
formazan in viable cells. MTT dissolved in PBS (50μg/ml) was added to
each well and plates were incubated for 2 hours. The medium was then
removed and 100μl DMSO was added to each well to lyse cells and
solubilize the formazan. A standard micro-plate reader (PowerWave 340,
BioTek) was used to determine the absorbance (600 nm). Each
experimental data point represents average values obtained from six
replicates and each experiment was performed at least twice.
2.4. 3H-thymidine assay
BC cells were plated in 96-well plates supplemented with 10% FBS MEM
at a density of 5× 10³ cells per well. After 24 hours, the cells were exposed
to drugs at the indicated concentrations for 48 hours. The medium was
removed and replaced with fresh MEM containing 1% FBS and 10 μCi/mL
[Methyl-³H]thymidine (MP Biomedicals) for 2 hours. The media was
subsequently removed. 100μl of 0.1mol/L KOH were then added to each
well. The cell lysates were harvested onto fiberglass filter membranes and
the amount of radioactivity quantified in a scintillation counter (1450

42

MICROBETA Trilux liquid scintillation and luminescence counter;
PerkinElmer life sciences). Each experimental data point represents
average values obtained from six replicates and each experiment was
performed at least twice.
2.5. Cell cycle analyses
Cells were plated in 6-well plates and maintained in 10% FBS MEM for 24
hours. Cells were then exposed to various concentrations of BGJ-398 for
48 hours or transfected with either FGFR1 or FGFR3 siRNA for 24 hours
(reaching ~75% to 85% confluence) before they were harvested by
trypsinization and pelleted by centrifugation. The pellets were then
resuspended in PI-FACS buffer (50 μg/mL propidium iodide, 0.1% Triton
X-100, and 0.1% sodium citrate dissolved in PBS). Propidium iodide
fluorescence was measured by fluorescence-activated cell sorting (FL-3
channel, Becton Dickinson) using the instrument’s cycle analysis software.
2.6. Anchorage independent growth assay
Human BC cell lines UM-UC3 and UM-UC13 wild type or non-targeted or
bFGF/FGFR1 silenced cells were plated at 1×104 cells per well in 6-wellplates supplemented with 10% FBS MEM containing 0.6% agar. Cells
were allowed to grow for 2 weeks. Images were acquired using an
Olympus IX inverted-phase contrast microscope. The total numbers of
colonies per random view (100×) and the average diameter of colonies
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per random view (100×) were determined using a SliderBook image
analyzer.
2.7. FGFR3 mutation analyses
DNA was isolated from BC cell lines using a genomic DNA extraction kit
(Qiagen). PCR was performed to amplify exons 7 and 10 using AmpliTaq
Gold DNA polymerase (Applied Biosystems) and the primers 5’CGGCAGTGGCGGTGGTGGTG-3’(sense) and 5’AGCACCGCCGTCTGGTTGGC-3’ (antisense) for exon 7 and 5’CCTCAACGCCCATGTCTTT-3’ (sense) and 5’AGGCAGCTCAGAACCTGGTA-3’ (antisense) for exon 10 (Sigma
Genosys). The following cycling variables were used: 95o C for 10 min, 35
cycles of 95o C for 30 s, then 65o C (exon 7) or 58o C (exon 10) for 30 s,
and 72o C for 30 s, followed by a final incubation at 72o C for 10 min.
Unincorporated primers and deoxynucleotides were removed using
shrimp alkaline phosphatase and exonuclease I (U.S. Biochemical).
Products were analyzed by Big Dye Terminator Cycle Sequencing
(Applied Biosystems), and the data were analyzed with Sequencing
Analysis 3.0 software (Applied Biosystems).
2.8. Real-time reverse transcriptase PCR analyses
Cells were harvested at ~75% to 85% confluence and total RNA was
isolated using mirVANATM miRNA Isolation Kit (Ambion, Life Science).
FGFRs and other genes of interests were analyzed by Taqman-based
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real-time PCR (ABI PRISM 7500; Applied Biosystems). The comparative
CT method was used to determine relative gene expression for each
target gene; the cyclophilin A gene was used as internal control to
normalize the amount of amplifiable RNA. Taqman primers was
purchased from Applied Biosystem as follows: E-cadherin,
Hs00170423_m1; TP63, Hs00978343_m1; ZEB1, Hs00232783_m1;
Vimentin, Hs00185584_m1; FGFR1, Hs00915142_m1; FGFR2,
Hs01552926_m1; FGFR3, Hs00179829_m1; FGFR4, Hs01106908_m1;
bFGF, Hs00266645_m; FABP4, Hs01086177_m1; CHOP,
Hs00358796_g1; PPARa, Hs00947536_m1; PPARb, Hs04187066_g1;
PPARg, Hs01115513_m1; GPX2, Hs01591589_m1; CYP2J2,
Hs00951113_m1; ERRFI1, Hs00219060_m1; FRS2, Hs00183614_m1;
FGFR3, Hs00179829_m1.
2.9. Immunoblotting analyses
Cells were harvested at ~75% to 85% confluence and lysed. Protein
concentrations were measured using the Bradford assay (Bio-Rad
Laboratories). Lysates were boiled in sample buffer (62.5 mmol/L TrisHCl (pH 6.8), 10% (w/v) glycerol, 100 mmol/L DTT, 2.3% SDS, 0.002%
bromophenol blue) for 5 minutes and cooled on ice for 5 minutes. Lysates
were separated on 8% or 12% SDS-PAGE gels at 110 volts in
electrophoresis buffer (25 mmol/L Tris-HCl (pH 8.3), 192 mmol/L glycine,
0.1% SDS) and then electrophoretically transferred onto nitrocellulose
membranes in transfer buffer (25 mmol/L Tris-HCl, 192 mmol/L glycine,
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20% methanol) for 1 hour at 100 volts. The membranes were incubated in
blocking buffer (5% nonfat milk in TBS: 10 mmol/L Tris-HCl (pH 8.0), 150
mmol/L NaCl) for 1 hour at room temperature while shaking and then
rinsed once briefly with TBS-T (TBS containing 0.1% Tween-20). The
membranes were then incubated with primary antibodies diluted 1:1000 in
blocking buffer overnight, washed, and then incubated with second
antibodies (anti-rabbit immunoglobulin, horseradish peroxidase–linked
F(ab)2 fragment from mouse) diluted 1:8,000 in blocking buffer for 1 hour
at room temperature while shaking. Immunoreactive proteins were
detected using enhanced chemiluminescence (Amersham Biosciences)
according to the manufacturer’s instructions.
2.10.

Boyden chamber invasion assays

Invasion chambers containing Matrigel-coated polyethylene terephthalate
membranes with 8μm pores were purchased from BD BioSciences in a
24-well plate format. Cells (2.5×105) were released from tissue culture
flasks using EDTA (1 mmol/L), centrifuged, suspended in a serum free
medium and placed in the upper compartments of invasion chambers.
Thirty percent fetal bovine serum medium was placed in the lower
compartments as a chemoattractant and invasion assays were carried out
for 48 hours. Each cell line or condition was plated in triplicate. To
examine cell invasion after exposure to BGJ-398, cells that had not
invaded were removed and the cells on the lower surface of the filter were
stained with Diff-Quick (American Scientific Products, McGaw Park, IL).
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Invasive activity was measured by counting the cells that had migrated to
the lower side of the filter. To evaluate invasion after silencing FGFR1 or
bFGF, membranes were removed after incubation for 48 hours at 37°C
and stained in propidium iodide (Sigma-Aldrich) without removing cells
from the upper surfaces of the membranes. The filters were mounted on
glass slides and analyzed by confocal microscopy at 100x magnification.
The planes of focus were adjusted so that the cells that had not invaded
could be distinguished from the invaded cells and counted in 8
independent fields. Invasive activity was measured by calculating ratios of
invaded to non-invaded cells.
2.11.

Gene silencing and exogenous overexpression

For small interfering RNA (siRNA) silencing, cells were reversetransfected with siRNA using RNAiMAX (Invitrogen) according to the
manufacturer’s guidelines and subjected to cell proliferation assays. In a
parallel experiment, siRNA transfected cells were harvested at 48 hours.
Total RNA and protein lysates were then analyzed for mRNA expression
by RT-PCR and protein expression by immunoblotting to confirm target
knockdown efficacy.
For stable short hairpin RNA (shRNA) knockdown and Precision
LentiORFs (pLOC) overexpression experiments, cells were plated in a 6well plates (105 cells/well) and transfected 24 hours later with the
construct of interest. Polybrene (Santa Cruz) was used to increase the
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efficiency of infection. Cells were continuously cultured. Five days after
transfection, fluorescence-activated cell sorting (FACS) was performed to
isolate the GFP-positive transfected cells followed by puromycin or
blasticidin selection. Total RNA and protein lysates were then collected to
confirm efficacy of knockdown and overexpression respectively.
2.12.

Gene expression profiling analyses

All transcriptome data were generated from triplicates. Total RNA of each
replicate was isolated independently using mirVANATM miRNA Isolation
Kit (Ambion, Life Technologies) and RNA purity and integrity were
measured by NanoDrop ND1000 (Thermo Scientific) and Agilent
Bioanalyzer (Agilent Technologies). High quality RNA was then used for
the synthesis of biotin-labeled cRNA using the Illumina RNA amplification
kit (Ambion) as described previously. Briefly, 500 ng total RNA was
converted to cDNA, then to cRNA by in vitro transcription, and finally
purified. 1.5 μg cRNA was fragmented and hybridized to Illumina humanHT12V4 chips (Illumina). The slides were washed, scanned with Bead
Station 500 (Illumina), and the signal intensities were quantified using
GenomeStudio (Illumina). Quantile normalization in linear models was
used to normalize the data, which were processed by established
techniques as described previously (citation).
BRB ArrayTools (version 4.2, National Cancer Institute) was used to
analyze the data. A class comparison tool within BRB ArrayTools was
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used to identify top genes that were differentially expressed. The software
uses a two-sample t test to calculate the significance of the observation
with false discovery rate (FDR) (P < 0.001). To visualize expression
patterns of genes, specific gene expression values were centered and
adjusted to a mean of zero and then subjected for clustering with Cluster
and TreeView (citation). Functional and pathway analyses were performed
using the Ingenuity Pathway Analysis (IPA) software (Ingenuity System).
The software contains a database for identifying networks and pathways
of interest in genomic data. The “upstream regulator” analysis function
was used to interpret the biological properties of gene profiling data.
2.13.

Animals study

Female athymic nude mice (NCr-nu) were purchased from the National
Cancer Institute. The mice were housed under specific pathogen-free
conditions in the Animal Core Facility at The University of Texas M. D.
Anderson Cancer Center. The facility has received approval from the
American Association for Accreditation of Laboratory Animal Care and in
agreement with current regulations and standards of the U.S. Department
of Health and Human Services, the U.S. Department of Agriculture, and
the NIH. The mice used in these experiments were 6 to 8 weeks old.
2.14.

Subcutaneous xenograft experiments

Subcutaneous injections of UM-UC-9 and UM-UC-14 into the right flank
were conducted using 106 cells/ 50μl Hank’s balanced salt solution
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(HBSS) without calcium and magnesium. The tumors’ major and minor
axes were measured with a caliper twice a week. The tumor volumes
(mm3) were calculated using the formula: width2 × length / 2. Tumors
were allowed to establish for 5 days before being randomized into groups
for experiments.
2.15.

Orthotopic xenograft experiments

Human BC cell line UM-UC-3 was transduced with a lentiviral vector
encoding luciferase (luc) and red fluorescent protein (RFP, mCherry) as
described previously (citation). After stable transduction with the luc-RFP
reporter, cells were sorted by Fluorescence Activated Cell Sorting (FACS)
using an Influx High-Speed sorter (BD Biosciences). Luciferase activity
was quantified in vitro using d-luciferin (150 μg/mL) and the IVIS
bioluminescence system (Xenogen Co.). To produce tumors in nude mice,
sub-confluent cultures of labeled UM-UC3 were lifted with trypsin, mixed
with 10% FBS MEM, centrifuged at 1,200 rpm for 5 min, washed in PBS,
and resuspended in HBSS. Cells were then injected orthotopically into the
bladder wall at a concentration of 5 × 105/50μL using a lower laparotomy.
Mice bearing metastases were euthanized 5 to 8 weeks after tumor cell
injection, the lymph node and distant metastases were excised, cut into
small pieces using scalpels, exposed to 1% trypsin for 20 minutes,
centrifuged (1,200 rpm for 5 min), and cultured in 10% supplemented
MEM. After FACS sorting, the recycled cells were sub-confluently cultured
and re-injected at a concentration of 2 × 105/50μL HBSS as described
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above. Thus, tumor cell recycling was performed three times in order to
select a highly metastatic UM-UC3 subpopulation which develops
metastases in ~75% of mice. For our therapy experiment, we injected the
4th cycle of recycled UM-UC3 at a concentration of 2 × 105/50μL. Mice
with detectable tumor growth at the time of the first imaging (5 days after
injection) were randomized into two groups (n = 7/group) and immediately
were administrated either vehicle control (1% Tween-80) or BGJ-398
(12.5 mg/kg) once daily by oral gavage.
2.16.

In vivo bioluminescence imaging

Bioluminescence imaging was conducted on an IVIS 100 imaging system
with Living Image software (Xenogen) as described elsewhere (citation).
In brief, animals were anesthetized with a 2.5% isoflurane/air mixture
before imaging and injected s.c. with 15 mg/mL of luciferin potassium salt
in PBS at a dose of 150 mg/kg. A digital gray-scale animal image was
acquired and a pseudo-colored image was overlaid representing the
spatial distribution of detected photons emerging from active luciferase.
Signal intensity was quantified as the sum of all detected photons within
the region of interest per second, separately counting each primary tumor
and each metastatic site.
2.17.

Collection of primary tumors and circulating tumor cells

Forty days after injection, when animals in the control group became
moribund, mice were anesthetized with isoflurane as described above. To
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measure the number of circulating tumor cells (CTCs), the maximal
amount of blood (600-1200μl) was collected by cardiac puncture using 1
ml syringe, 22 gauge needle, and heparin-coated collection tubes as
described previously. Mice were then euthanized with carbon monoxide.
For further blood processing, red blood cells were lysed twice for 5 min
with 10ml ACK lysis buffer (Invitrogen), and centrifuged for 5 min at 1200
rpm in Eppendorf tubes. The pellet was finally lysed and further processed
for total RNA isolation using the mirVANATM miRNA Isolation kit (Ambion,
Life Science). To quantify the CTCs, absolute quantification of real-time
PCR analysis (Step One; Applied Biosystems) was used to generate cycle
threshold (CT) values for human specific HLA-C primer (Hs00740298_g1)
for each sample. RT-PCR analysis of the blood samples was run alone
with standard isolates (0, 2, 20, 200, 2000, and 20,000 UM-UC3 cells in
100μl mouse blood). CT values of the standards were used to create a
standard curve for UM-UC3 CTCs, and the number of CTCs of each blood
sample was calculated accordingly.
2.18.

Statistics

Statistical analysis was performed using GraphPad Prism Software
(GraphPad). As appropriate, raw data or percentages were compared by
unpaired Student’s t-test. Tumor growth curves in xenografts were
analyzed using Two-Way ANOVA with Bonferroni multiple comparisons.
Statistical significance was set at p < 0.05.
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CHAPTER 3. FGFR1 AND FGFR3 MEDIATE
DISTINCT FUNCTIONS IN HUMAN BLADDER
CANCER GROWTH AND METASTASIS
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3.1. Results
3.1.1. Genome wide expression profiling of FGFRs and correlation
with EMT markers.
Our previous studies [115,147] revealed a binary pattern of heterogeneity
in a panel of 30 urothelial cancer cells. More specifically, it was shown that
UC cells can be grouped into two major categories in terms of biomarker
expression, forming: “epithelial” and “mesenchymal” subsets. In this study,
we first analyzed the expression of all four FGF receptors and the
dominant cancer-associated FGF ligand, FGF2/basic FGF, at the mRNA
level in the panel of 30 cell lines using whole genome expression profiling
(Illumina HT12V4 Platform) and compared the pattern of FGFR/bFGF
expression to markers of the “epithelial” and “mesenchymal” subsets. The
expression of FGFR3 correlated with E-cadherin and p63 [148-150], which
suggested FGFR3 was expressed by “epithelial” UC cells. In contrast, the
expression of FGFR1 and FGF2 directly correlated with vimentin, a
“mesenchymal” marker (Figure 3.1). To more accurately define the
“epithelial” and “mesenchymal” subsets within the panel of UC cells, we
then used quantitative real-time reverse transcriptase PCR (RT-PCR) to
measure the expression of two “epithelial” markers (E-cadherin and p63)
and two “mesenchymal” markers (Zeb-1 and vimentin) in the cells. As
shown in the Figure 3.2, the expression of E-cadherin directly correlated
with p63 expression while inversely correlating with expression of Zeb-1
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Figure 3.1 Expression of FGFR1, FGFR3 and bFGF in distinct
subsets of human urothelial cancer cells. Correlation of FGFR1,
FGFR3 and bFGF with canonical EMT markers. mRNA levels were
measured by whole genome mRNA expression profiling (Illumina). The
heatmap illustrate the expression of FGFR1, FGFR3, FGF2, p63 (TP63),
E-cadherin (CDH1), Slug (SNAI2) and vimentin (VIM).
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Figure 3.2 Expression of EMT markers measured by RT-PCR. Relative
levels of “epithelial” markers E-cadherin (CDH1) and p63 (TP63), and
“mesenchymal” markers Zeb-1 (ZEB1) and vimentin (VIM) were measure
by RT-PCR. Expression levels were normalized to UM-UC16.
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and vimentin. These data indicated that the “epithelial” and
“mesenchymal” markers are expressed in a non-overlapping manner
among the majority of UC cell panel in that only two cell lines (UM-UC18
and 1A6) co-expressed “epithelial” and “mesenchymal” markers (Figure
3.2).
3.1.2. Correlation between E-cadherin and FGFR/bFGF expression
in urothelial cancer cells.
To fully understand the relationship between EMT markers and
FGFR/bFGF expression, we first examined expression of FGFRs1-4 and
bFGF (FGF-2) by RT-PCR. In line with the gene expression profiling data,
the expression of FGFR1 and FGF-2 were enriched in the “mesenchymal”
subset (UM-UC3, UM-UC13, T24, BV and UM-UC12), whereas FGFR3
was primarily expressed within “epithelial” subset (RT4, UM-UC14, RT112
and SW780) (Figure 3.3). Although FGFR2 expression also appeared to
be concentrated within the “epithelial” subset and FGFR4 expression in
“mesenchymal” subset respectively, their levels of expression were lower
than the levels of FGFR3, FGFR1 or bFGF, which is consistent with recent
studies [103]. We then used nonparametric correlation analyses to confirm
that expression of FGFR3 correlated strongly with E-cadherin expression
(Spearman r=0.8155, p<0.0001, Figure 3.4) but inversely with expression
of “mesenchymal” markers (Table 3.1). On the contrary, expression of
FGFR1 and bFGF correlated strongly and directly with Zeb-1 expression
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Figure 3.3 Expression of FGFRs 1-4 and bFGF. The relative mRNA
levels were measured by quantitative real-time RT-PCR. The cell lines in
each panel are organized by relative E-cadherin expression (low to high,
from left to right, refer to Figure 3.2).
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Figure 3.4 Relationship beteween FGFR/bFGF and EMT markers.
Scatterplots depicting the relationships between expression of FGFR3,
bFGF, FGFR1, and EMT markers. Nonparametric correlation analyses
were used to evaluate the relationships between FGFR3 and E-cadherin
(CDH1) expression, FGFR1 and ZEB1 expression, bFGF and ZEB1
expression, and bFGF and FGFR1 expression. Correlation coefficients
and p values are indicated on the figure.
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Table 3.1 Correlation between FGFR/bFGF and EMT markers. The
figure displays the results of the nonparametric correlation analyses.
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presence of an inverse relationship between markers.
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(Spearman r=0.799, p=0.0001 for FGFR1 and r=0.6198, p=0.008 for
bFGF, Figure 3.4). In addition, FGFR1 and bFGF correlated directly with
each other as we expected (Figure 3.4). We then investigated whether the
pattern of differences observed in mRNA level could be translated into
protein level in a subset of the cell lines by immunoblotting. We found that
FGFR3 but not FGFR1 was expressed in “epithelial” cell lines UM-UC14,
RT112 and RT4. Conversely, FGFR1 but not FGFR3 was expressed in
“mesenchymal” cell lines UM-UC3, UM-UC12 and UM-UC13. Although
bFGF was expressed in all 6 cell lines, “mesenchymal” cell lines (UMUC3, UM-UC12 and UM-UC13) indeed expressed more bFGF than
“epithelial” cell lines (UM-UC14, RT112 and RT4) (Figure 3.5). Together,
these data suggested that FGFR1/bFGF and FGFR3 probably drive
separate functions in non-overlapping “mesenchymal” and “epithelial” UC
cells.
3.1.3. Effects of BGJ-398 on proliferation.
Recent studies indicated that FGFR inhibition blocks cell proliferation in
human UC cells [104,126]. We therefore examined the effects of BGJ-398
on proliferation in 17 UC cell lines to characterize the scale of
heterogeneity of drug sensitivity. Cells was incubated with increasing
concentration of BGJ-398 for 48 hours and then subjected to MTT assay
to measure drug induced cytotoxicity and/or growth arrest. We identified 4
cell lines (UM-UC14, SW780, RT4 and RT112) that were drug sensitive as
≥50% growth inhibition at concentrations of 1μM or lower (Figure 3.6A).
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Figure 3.5 Baseline expression of FGFR1, FGFR3 and bFGF proteins
in subsets of epithelial and mesenchymal UC cells. FGFR1, FGFR3
and bFGF in 3 representative “epithelial” (UM-UC14, RT4 and RT112) and
3 “mesenchymal” (UM-UC3, UM-UC12 and UM-UC13) cell lines were
measured by immunoblotting.
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A.

B.

Figure 3.6 Effects of BGJ-398 on cell proliferation in the drugsensitive cells. A. cells were incubated for 48 h in the presence of the
indicated concentrations of BGJ-398 and cell growth was measured by
MTT reduction. Mean ± SEM, n = 6. B. UM-UC14 or RT4 cells were
incubated with the indicated concentrations of BGJ-398 and the
percentages of cells within each cell cycle quadrant were quantified by
propidium iodide staining and FACS analysis. Mean ± SEM, n = 3.
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To further determine the relative contribution of cell death versus growth
arrest to these effects, we directly measured cell cycle arrest and
apoptosis by propidium iodide (PI) staining and FACS analysis after
exposing UM-UC14 and RT4 cells to increasing concentration of BGJ-398
for 48 hours. We observed increases in percentage of cells in G1 phase
whereas a decreases in percentage of cells in S phase in both cell lines
with increasing concentrations of BGJ-398. More specifically, the
percentage of cells in G1 phase increased from 47.5% and 54% to 74.2%
and 69.1%, and in parallel the percentages of cells in S phase decreased
from 33.5% and 25% to 2.7% and 8.8%, in the BGJ-398 treated UM-UC14
and RT4 respectively (Figure 3.6B). On the contrary, BGJ-398 exposure
did not cause any apoptosis at concentration lower than 10 μM in either of
the cell lines (data not shown). These data indicated that BGJ-398
induced cytostatic effects on UC cells in vitro.
Recent studies revealed FGFR3 activating mutations and overexpression
as potential mechanisms contributing to response to FGFR antagonist
[64,151]. We therefore examined the relationship between BGJ-398
sensitivity and the presence of activating FGFR3 mutations. We first
identified 5 cell lines (UM-UC6, UM-UC14, UM-UC15, UM-UC16 and UMUC17) that contained activating FGFR3 mutations within our panel by
exon sequencing (Table 3.2). Strikingly, only one of the 5 cell lines was
BGJ-398 sensitive. However, FGFR3 mRNA expression correlated
strongly with drug sensitivity using nonparametric correlation analysis
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Table 3.2 FGFR3 mutation status in human bladder cancer cells. The
presence of activating FGFR3 mutations was determined by exon
sequencing. Note that among the 5 cell lines within the panel that contain
activating mutations, only one (UM-UC14) is sensitive to BGJ-398.
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(Spearman r=0.7247 p=0.01, Figure 3.7), whereas no clear correlation
was observed between FGFR1 mRNA expression and sensitivity to BGJ398 (Spearman r=-0.2931 p=0.2536, Figure 3.9)
Given the non-overlapping pattern of FGFR3 and FGFR1 expression, the
indicated results suggested that FGFR3 was more essential than FGFR1
in driving cell proliferation in “epithelial” UC cells. We then used RNAi to
directly test this hypothesis. BGJ-398 sensitive cells were transfected with
either FGFR3 or FGFR1 siRNAs to knock down the targeted gene and cell
proliferation was measured by MTT assay. Quantitative PCR confirmed
FGFR3 knockdown efficiencies of 50% and >80% in the RT4 and UMUC14 with FGFR3 siRNAs compared to non-specific siRNA control,
respectively. The result was also confirmed by Immunoblotting at protein
level (Figure 3.8). The corresponding effect of FGFR3 silencing was very
similar to BGJ-398 exposure. Cell proliferation was reduced by 60%
and >90% in RT4 and UM-UC14 cells transfected with FGFR3 siRNA,
respectively (Figure 3.9). Cell cycle analyses revealed that FGFR3
knockdown increased the percentage of cells in G1 phase and decreased
the percentage of cells in G2 phase, which is consistent with the MTT
results. However, FGFR1 silencing had no significant effect on
proliferation and cell cycle in both RT4 and UM-UC14(Figure 3.10).
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Figure 3.7 Sensitivity to the anti-proliferative effects of BGJ-398
correlates with FGFR3 expression but not with the presence of
activating FGFR3 mutations. The level of growth inhibition observed
after 48 h exposure to 1 μM BGJ-398 (as measured by MTT assays) was
correlated with the relative level of FGFR3 (left panel) or FGFR1 (right
panel) mRNA expression in a panel of 17 human BC cell lines.
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Figure 3.8 Efficiency of FGFR3 silencing measured by quantitative
RT-PCR and immunoblotting. A. measurement of FGFR3 silencing
efficiency by quantitative PCR. B. measurement of FGFR3 silencing
efficiency by immunoblotting.
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B.

Figure 3.9 Effects of FGFR3 knockdown on cell proliferation. UMUC14 or RT4 cells were transiently transfected with either non-targeting
(NT) or FGFR3-specific siRNAs and, A. cell growth was measured at 48 h
by MTT reduction. Mean ± SEM, n = 6. B. percentages of cells within
each phase of the cell cycle were quantified by propidium iodide staining
and FACS analysis. Mean ± SEM, n = 3.
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Figure 3.10 Effects of FGFR1 knockdown on FGFR1 expression and
proliferation in RT4 and UM-UC14 cells. UM-UC14 or RT4 cells were
transiently transfected with either non-targeting (NT) or FGFR1-specific
siRNAs and, cell growth was measured at 48 h using MTT. Mean ± SEM,
n = 8. And, the percentages of cells within each phase of the cell cycle
were quantified by propidium iodide staining and FACS analysis. Mean ±
SEM, n = 3.
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3.1.4. Effects of BGJ-398 on invasion.
Our data indicated the “mesenchymal” UM-UC3 and UM-UC13 were
resistant to the growth arrest effect of BGJ-398 (Figure 3.11A) although
both of they expressed relatively high levels of FGFR1. Given that
migration, invasion and metastasis are key characters of “mesenchymal”
cells [150], we examined the effects of BGJ-398 on invasion in UM-UC3
and UM-UC13 while two “epithelial” BGJ-398 resistant cells (UM-UC6 and
UM-UC9) were used as controls. The cells were exposed to increasing
concentrations of BGJ-398 and invasion was measured using modified
Boyden chambers. BGJ-398 effectively inhibited invasion in the
“mesenchymal” UM-UC3 and UM-UC13 cells in a concentration
dependent manner but not in the “epithelial” UM-UC6 and UM-UC9 cells
(Figure 3.11B).
Because our previous data suggested a direct correlation between
bFGF/FGFR1 and “mesenchymal” markers (Figure 3.3), we then
hypothesized that bFGF/FGFR1 are involved in the regulation of invasion
in “mesenchymal” cells. To directly test the hypothesis, we first transfected
UM-UC3 and UM-UC13 cells with lentiviral shRNAs to stably silenced the
expression of either bFGF or FGFR1. The efficiency of targeted
knockdown was confirmed by both quantitative PCR at mRNA level and
immunoblotting at protein level (Figure 3.12). We then quantified invaded
cells in these bFGF/FGFR1 stably silenced cells and compared it to the
results from non-specific control and parental cells using modified Boyden
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A.

B.

Figure 3.11 Effects of BGJ-398 on cell growth and invasion in two
“mesenchymal’ (UM-UC3, UM-UC13) and two “epithelial” (UM-UC6,
UM-UC9) cell lines. Growth inhibition was measured at 48 h by MTT
reduction. Mean ± SEM, n = 6. Invasion was measured using modified
Boyden chambers and standard light microscopy as described in Materials
and Methods. Mean ± SEM, n = 3.
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A.

B.

Figure 3.12 FGFR1 or bFGF silencing in cells transduced with
lentiviral shRNAs. A. Relative mRNA levels were measured by
quantitative real-time RT-PCR and B. protein levels were measured by
immunoblotting.
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chambers and confocal microscopy. In UM-UC3 cells, the percentage of
invading cells was reduced from 85% in the parental cells or cells
transduced with a control lentiviral construct to 54.5% in bFGF KD cells
(P=0.0029) and 63.8% in FGFR1 KD cells (P=0.0038), respectively.
Similarly, in UM-UC13 cells, the levels of invasion were reduced from 82%
in parental cells or cells transduced with the non-targeting lentivirus to
64.8% in the bFGF KD cells (P=0.0146) and 52.4% in FGFR1 KD cells
(P=0.0018) (Figure 3.13). Together, the data confirmed that bFGF and
FGFR1 both promoted invasion in “mesenchymal” BC cells.
3.1.5. Effects of BGJ-398 on tumor growth and metastasis.
Although in vitro models are excellent tools for studying molecular
mechanisms, the process of cancer metastasis is regulated by tumorstromal interactions that cannot be modeled well in vitro. Therefore, in
order to better define the effects of BGJ-398 on primary tumor growth
versus metastasis in “mesenchymal” BC cells, we first isolated a highly
metastatic form of UM-UC3 using orthotopic “recycling” in nude mice
[152]. We transduced the cells with a lentiviral vector encoding luciferase
and red fluorescent protein (RFP), which enabled us to monitor primary
tumor growth and metastasis non-invasively by luciferase imaging and to
isolate circulating tumor cells (CTCs) by cell sorting. After 3 rounds of
recycling, the UM-UC3 cells formed orthotopic tumors in 100% of mice
and consistently produced metastases to lymph nodes, lungs, and bone in
over 70% of mice. We then implanted 200,000 of the recycled UM-UC3
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Figure 3.13 Effects of FGFR1 or bFGF silencing on invasion. The
percentages of cells that invaded through Matrigel in modified Boyden
chambers were quantified by propidium iodide staining and confocal
microscopy. Representative confocal images were displayed at right panel
where the nuclei of the cells that invaded are pseudo-colored blue and the
cells that did not invade are depicted in red.
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cells orthotopically in nude mice and initiated therapy with BGJ-398 or
vehicle (via oral gavage) once primary tumors were well established (on
day 8), monitoring tumor growth and metastasis biweekly by IVIS imaging
(Figure 3.14; 3.15). Interestingly, primary tumors in the mice treated with
BGJ-398 appeared to grow slightly faster than controls, although the
differences in growth rates were not statistically significant (Figure 3.14;
P>0.05). In contrast, BGJ-398 strongly inhibited the development of
metastases and CTCs. Specifically, 5 out of 7 mice within the control
group developed lymph node metastasis by day 15, and two of these
subsequently developed bone and lung metastasis at day 36 (Fig. 3.15
right panel). However, we detected only 1 lymph node metastasis in the 7
animals within the BGJ-398 treatment group. When we quantified total
metastatic burden using luciferase imaging, the differences between the
vehicle and BGJ-398 treatment groups were highly significant (Figure
3.15; p = 0.0078). Finally, we quantified the numbers of circulating tumor
cells in the mice at the time of sacrifice on day 40 by measuring human
HLA-C levels in whole peripheral blood by quantitative PCR. CTC
numbers within the control group ranged from 325 to 336,008 cells (mean
= 158,977), whereas CTC numbers in the treated group ranged from 160
to 370 (mean = 243.6) (Figure 3.16; p < 0.01). Together, the results
demonstrated that BGJ-398 had no inhibitory effect on the growth of UMUC3 primary tumors but did block tumor cell extravasation into the
vasculature (as measured by CTC production) and metastasis.
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Figure 3.14 Effects of BGJ-398 on primary tumor growth in mice
bearing orthotopic UM-UC3 xenografts. Luciferase-labelled,
orthotopically recycled UM-UC3 cells were implanted into the bladders of
nude mice, and tumors were allowed to grow for 8 days prior to initiating
therapy with BGJ-398 (daily via oral gavage). Tumor growth was
measured biweekly by luciferase imaging. Mean ± SEM from 6 (control)
or 7 (treated) mice per group.
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Figure 3.15 Effects of BGJ-398 on metastasis in mice bearing
orthotopic UM-UC3 xenografts. Whole animal metastatic burdens were
determined non-invasively by luciferase imaging. Mean ± SEM, n = 6
(control mice) or 7 (treated mice). Representative whole body luciferase
images taken just prior to the initiation of therapy and at the conclusion of
the experiment were displayed at right panel.
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Figure 3.16 Effects of BGJ-398 on UM-UC3 CTC production. CTC
numbers were estimated by measuring human HLA levels in isolated
whole blood by quantitative PCR; cell numbers were determined using a
UM-UC3 standard curve. The scatterplot displays the results obtained
from each animal; the lines denote the mean values for each group.
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Figure 3.17 Effects of bFGF or FGFR1 silencing in long-term
proliferation assays. MTT results obtained in 5-day assays. Mean ±
SEM, n = 6. *p<0.05.
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3.2. Discussion
FGFR3 is frequently activated by mutation [42,151,153] in both muscle
invasive and non-invasive urothelial cancers, where it appears to drive cell
proliferation [101,102]. Recent studies also revealed the prevalence of
FGFRs overexpression, specifically overexpression of FGFR1 [103] and
FGFR3 [154,155], which may identify as oncogenic addiction in urothelial
cancer. Taken together, these data identify FGFR1 and FGFR3 as two of
the most attractive targets in clinical development in bladder cancer
[105,154]. However, there exists a significant heterogeneity in response to
FGFR inhibitors [64,156-158] in BC cells based on the results published to
date, and it is presently unclear what factors are driving sensitivity to
FGFR inhibitors. The heterogeneity and the unclear underlying
mechanisms could significantly jeopardize the identification of the
appropriate subset of BC patients who could benefit markedly from the
FGFR targeted therapy.
Based on recent studies, it is likely that FGFR3 activating mutation (i.e.
S249C) determines the FGFR3 dependency which drives the sensitivity to
selective and non-selective FGFR inhibitors. However, in this study, our
data demonstrated that the presence of an FGFR3 activating mutation
alone does not predict sensitivity to BGJ-398 in a panel of human UC
cells. Conversely, FGFR3 mRNA expression levels did correlate well with
the sensitivity to BGJ-398 (Figure 3.7), suggesting a link between FGFR3
overexpression and FGFR3 dependency. More specifically, among BC
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cell lines bearing FGFR3 activating mutations, the majority of them were
not sensitive to BGJ-389 in this study (UM-UC6, UM-UC15, UM-UC16,
UM-UC17) or other FGFRs inhibitors (94-10, 97-18, J82) [156,158],
though only two of them were highly sensitive to BGJ-398 or other
inhibitors [156,157]. In contrast, at least one FGFR3 wild-type cell line
(UM-UC1) was as sensitive to BGJ-398 as the most sensitive FGFR3
mutant cells [156]. In addition, two other cell lines (RT4, RT112) bearing
the FGFR3-TACC3 translocation were among the cell lines that are
sensitive to BGJ-398. Although little is unknown about the underlying
mechanism regarding this heterogeneity, a recent study provided a
possible explanation, where FGFR3 mutant cells exhibited an escape
mechanism through pathway redundancy to rescue the proliferation
refractory from FGFR inhibition [132].
More importantly, our results indicated a non-overlapping pattern between
FGFR3 and FGFR1 expression in the panel of human BC cells we
studied, and interesting, cells with high expression level of FGFR1 were all
relatively resistant to BGJ-398. Collectively, these data demonstrated that
FGFR3 expression is a more important determinant than FGFR1
expression in driving cell proliferation in the specific cells we studied. In
addition, our data demonstrated that the primary effects of FGFR inhibition
by BGJ-398 are cytostatic rather than cytotoxic, which indicated the
potential value of FGFR inhibition lies in the combination with conventional
chemotherapy or radiation therapy in clinical development. Indeed, in
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future studies we are going to examine the hypothesis that FGFR
inhibition could improve the effect of conventional chemotherapy or
radiation therapy by promoting their cytotoxic effects. With respect to
clinical development, it is worth noting that all of the human UC cell lines
with a possible exception of RT4 are derived from muscle invasive UC.
Due to this limitation, it is possible that the cell line studies underestimate
the potential efficacy of FGFR3 inhibition in non-muscle invasive UCs. In
fact, a majority of non-muscle invasive BC contain FGFR3 activating
mutations, strongly suggesting that FGFR antagonists could have strong
clinical activity in them.
Interestingly, our data also demonstrated that FGFR1 played a significant
role in cell invasion and tumor metastasis even though FGFR1 was less
important than FGFR3 in promoting cell proliferation. More specifically,
FGFR1 signaling repression by either BGJ-398 or specific FGFR1
silencing led to reduced cell invasion in vitro (Figure 3.11, 3.13). In
addition, BGJ-398 inhibited CTC production and metastasis without
decreasing primary tumor growth in vivo (Figure 3.14, 3.15, 3.16), which
seems to contradict a recent study suggesting the role of FGFR1 in driving
both cell proliferation in vitro and tumor growth in vitro. However, our
conclusion that FGFR1 did not drive cell proliferation in some
“mesenchymal” UC cells was based on MTT assay to measure short-term
effects of BGJ-398. We reached to the same conclusion that was
advanced in previous work (blocking FGFR1 impaired cell proliferation)
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when we measured long-term effects of stable silencing FGFR1 using
colony formation assays (Figure 3.17), which indicated the importance of
FGFR1 for initiation but not maintenance of cell proliferation in UC cells.
Furthermore, our in vivo experiment was based on FGFR targeted therapy
by BGJ-398 in mice with established orthotopic tumors whereas the
previous work relied on stable silencing of FGFR1, consistent with the
idea that FGFR1 is important for tumor initiation but may be not for
maintenance of tumor growth. It is also worth noting that several other
studies also suggested a role of FGFR1 in cell invasion and tumor
metastasis [104].
Finally, our results demonstrated distinct effects of FGFR inhibition, in that
FGFR3 inhibition blocked cell proliferation, whereas FGFR1 inhibition
suppressed cell invasion and metastasis. It is presently unclear why the
differential effects exist given that the effects on proliferation and invasion
were clearly linked to inhibition of the same signal transduction pathway
(MAPK/Erk signaling) [47,49,104]. One possible explanation was that the
different effects are a consequence of the distinct biological difference
between the epithelial and mesenchymal phenotype. Our data suggested
a non-overlapping expression pattern of FGFR1 versus FGFR3 in UC cell
lines in that FGFR1 primarily expressed in mesenchymal phenotype,
whereas FGFR3 correlated well in epithelial phenotype (Figure 3.1, 3.2,
3.3). It is highly possible that the “epithelial” cells are more dependent on
autocrine growth factors for G1/S transition and proliferation than
84

“mesenchymal” cells, whereas the “mesenchymal” cells rely on growth
factors for invasion rather than other cell functions. Our results also shed
the light on possible clinical translation in muscle invasive urothelial
tumors or where a subset of low grade non-muscle invasive urothelial
tumors progress into muscle-invasive tumors. FGFRs inhibition in
conjunction with conventional chemotherapy could be valuable to target
these tumors and benefit patient sub-groups if appropriate biomarkers can
be identified and deployed to pinpoint the subsets of tumors.
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CHAPTER 4. A PPARγ-FABP4 TRANSCRIPTIONAL
COMPLEX REGULATES EGFR DEPENDENCY IN
HUMAN BLADDER CANCER CELLS
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4.1. Result
4.1.1. Sensitivity to EGFR or FGFR inhibitors is confined to the
“epithelial” subset of bladder cancer (BC) cell lines
Previous studies showed that 5 urothelial cancer (UC) cell lines (UM-UC4,
UM-UC5, UM-UC7, UM-UC9 and UM-UC16) were sensitive to EGFR
inhibitor gefitinib at clinically relevant concentration (≤ 1μM) in a panel of
25 human urothelial cancer cell lines [115,147]. A recent screening of the
FGFR inhibitor BGJ-398 in the same panel also identified 4 different cell
lines (UM-UC14, SW780, RT4 and RT112) that were sensitive at clinically
relevant concentration (≤ 1μM) [70]. We first confirmed that the same cell
lines were sensitive to the structurally distinct FGFR inhibitor AZD4547 but
not EGFR inhibitor gefitinib using both MTT assay (Figure 4.1) and
thymidine incorporation assay (Figure 4.2). We also confirmed that the
other 4 UC cell lines (UM-UC4, UM-UC5, UM-UC7, UM-UC9) were still
sensitive to the EGFR inhibitor gefitinib but not FGFR inhibitor AZD4547
as measured by both MTT assay (Figure 4.1) and thymidine incorporation
assay (Figure 4.2). In addition, we also tested drug responses in vivo to
further verify the observation. We found that UM-UC9 subcutaneous
xenografts were sensitive to gefitinib and that UM-UC14 subcutaneous
xenografts were sensitive to AZD4547 in vivo. The in vivo effects of the
drugs were associated with decreased proliferation as measured by Ki-67
immunohistochemistry (Figure 4.3).
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Figure 4.1 Differential effects of the FGFR inhibitor AZD4547 and the
EGFR inhibitor gefitinib in human UC cells. The human UC lines UMUC4, UM-UC5, UM-UC7, UM-UC9, UM-UC14, RT4, RT112, and SW780
were exposed to either AZD4547 or gefitinib at the indicated
concentrations, and cell proliferation was measured by MTT assays,
normalized to controls (mean ± SEM).
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Figure 4.2 Differential effects of the FGFR inhibitor AZD4547 and the
EGFR inhibitor gefitinib in human UC cells. The human UC lines UMUC4, UM-UC5, UM-UC7, UM-UC9, UM-UC14, RT4, RT112, and SW780
were exposed to either AZD4547 or gefitinib at the indicated
concentrations, and cell proliferation was measured by thymidine
incorporation assay, normalized to controls (mean ± SEM).
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Figure 4.3 Growth inhibition of gefitinib or AZD4547 in subcutaneous
xenograft models. UM-UC9 and UM-UC14 cells were injected
subcutaneously into nude mice. Tumors were allowed to establish for 5
days prior to treatment with either vehicle (control) or gefitinib (UM-UC9; n
= 12 / group) or AZD4547 (UM-UC14; n = 9 / group) via oral gavage.
Tumor volumes (mm3) were calculated using the formula width2 x length /
2, and depicted as means ± SEMs. Tumor tissue was harvested, fixed and
stained for Ki-67 using immunohistochemistry.
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These results suggested that sensitivity to either gefitinib or AZD4547
were confined to an ‘epithelial’ subset of UC cell lines characterized by
high levels of E-cadherin expression (an epithelial marker) [70,147] and
that sensitivity to either drug was mutually exclusive. Specifically, all of the
cell lines that were sensitive to gefitinib were resistant to AZD4547, and all
of the cell lines that were sensitive to AZD4547 were resistant to gefitinib
(Figure 4.1 and 4.2). We then confirmed these in vitro results using
orthotopic in vivo models by conducting four-arm studies in UM-UC9 (n
=11 / group) and UM-UC14 (n = 9 / group) tumor-bearing nude mice.
Consistent with the in vitro results, we found that once-daily oral
administration of gefitinib (12.5 mg/kg) produced strong tumor growth
inhibition in UM-UC9. On the contrary, AZD4547 (12.5 mg/kg) had no
effect on tumor growth by itself. In addition, the combination of gefitinib
and AZD4547 (each at 12.5 mg/kg) did not result in any additional effect
(Figure 4.4, upper left panel). Conversely, AZD4547 but not gefitinib (each
at 12.5 mg/kg) produced strong growth inhibition in the orthotopic UMUC14 tumors. In addition, combination of AZD4547 and gefitinib produced
no added benefit as compare to single agent therapy with AZD4547
(Figure 4.4, lower left panel). Measurements of tumor weights at sacrifice
(after 4 weeks of therapy) confirmed the imaging results (Figure 4.4, right
panel). Together, these date indicated sensitivity to either EGFR or FGFR
inhibitor is non-overlapping and mutually exclusive both in vitro and in
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Figure 4.4 Effects of AZD4547, gefitinib, and AZD4547 plus gefitinib
on the tumor growth of orthotopic xenografts. Luciferase-labeled UMUC9 and UM-UC14 were orthotopically implanted into the bladders of
nude mice. Tumors were allowed five days to establish prior to treatment.
Animals were given AZD4547 (12.5mg/kg), gefitinib (12.5mg/kg), or a
combination of both TKIs (12.5mg/kg each), or vehicle control (1% Tween
80, 99% deionized water) once daily for four weeks by oral gavage (n = 9 /
group). Tumor growth was repeatedly measured non-invasively by in vivo
bioluminescence imaging. The results are expressed as photon counts
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(mean ± SEM). In addition, UM-UC9 and UM-UC14 primary tumors were
harvested at sacrifice and weighed after four weeks of treatment. Tumor
weights (mg) are indicated as means ± SEM.
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vivo. Therefore, we identified 4 UC cell lines (UM-UC14, SW780, RT4 and
RT112) as FGFR dependent and another discrete 4 cell lines (UM-UC4,
UM-UC5, UM-UC7, UM-UC9) EGFR dependent within the panel.
We also noticed that several of the UC cell lines that contain activating
FGFR3 mutations are resistant to FGFR inhibitors in vitro such as UMUC6 [70]. Since three-dimensional growth and/or the tumor
microenvironment could have major effects on drug sensitivity [159], we
examined the effects of AZD4547 on orthotopic tumors (n = 8 mice /
group) derived from the ‘epithelial’ UM-UC6 cells, which contain an
activating S249C mutation but are resistant to FGFR inhibitors in vitro [70].
We observed that AZD4547 alone had no effect on tumor growth (Figure
4.5), confirming and extending our previous conclusion that FGFR3
mutational status alone is not predictive of FGFR inhibitor sensitivity [70].
4.1.2. Sensitivity to AZD4547 correlates with A-FABP/FABP4
expression
To determine the biological mechanisms underlying the differential
sensitivities of UC cells to AZD4547 and gefitinib, we performed mRNA
expression profiling using the Illumina platform (Human HT-12 V 4.0) to
compare the baseline mRNA expression profiles in the FGFR- and EGFRdependent UC cells. We found that several of the top genes that were
differentially expressed between them were components of the PPARγ
transcriptional pathway (Figure 4.6). Specifically, high baseline expression
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Figure 4.5 Effects of AZD4547 in orthotopic UM-UC6 tumors. UM-UC6
cells were orthotopically implanted into the bladder. Tumors were allowed
five days to establish prior to treatment. Animals were given either vehicle
or AZD4547 (12.5 mg/kg) via oral gavage (n = 8 / group). Primary tumor
growth was continuously measured by non-invasive in vivo
bioluminescence imaging. Photon counts are indicated as mean ± SEM.
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Figure 4.6 Differential expression of FABP4, CYP2J2, GPX2 and
FGFR3 in a panel of urothelial cancer cell lines (n = 25). Whole
genome mRNA expression profiling (Illumina platform) was used to
measure mRNA expression. The heat map depicts the expression of
CYP2J2, FABP4, GPX2 and FGFR3. Urothelial cancer cell lines are colorcoded according to the corresponding sensitivity to gefitinib (blue) or
AZD4547 (red).
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of fatty acid binding protein 4 (FABP4, Adipocyte-FABP), characterized
the FGFR-dependent cell lines, whereas FABP4 was essentially
undetectable in the EGFR-dependent cells (a 55-fold difference) (Figure
4.6). We confirmed these findings by both quantitative PCR and
Immunoblotting (Figure 4.7). Additionally, the FGFR-dependent cells
expressed high levels of CYP2J2 (7-fold difference), the cytochrome P450
isoform that produces PPAR ligands [160], and GPX2 (18 fold difference),
a known downstream target of PPARγ signaling [160,161] (Figure 4.6).
These results were also confirmed by quantitative PCR (Figure 4.8). To
further validate that the FGFR-dependent cells displayed baseline gene
expression patterns consistent with PPARγ activation, we then used a
hepatocyte-derived PPARγ gene set [162] to conduct gene set enrichment
analyses (GSEA) to test degree of PPARγ signal enrichment in the FGFRdependent cells as compared to the EGFR-dependent cells. The results
indicated that PPARγ regulating genes were enriched in the FGFRdependent cells with a normalized enrichment score (NES) of 1.83 (Figure
4.9, P=0.002). Together, these results suggested a strong correlation
between PPARγ activation, more specifically constitutive expression of
FABP4
4.1.3. PPARγ modulates FABP4 expression in UC cells
FABP4 functions as a specific co-activator for PPARγ by binding PPARγ
ligands in the cytosol, transferring and facilitating ligand binding to PPARγ
via a mechanism that has been termed “ligand tunneling”, and promoting
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Figure 4.7 Confirmation of differential FABP4 expression in the panel
of UC cells. FABP4 mRNA and protein expression were measured by
quantitative PCR and immunobloting respectively.
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Figure 4.8 Expression of CYP2J2 and GPX2 in the EGFR (UM-UC4,
UM-UC5, UM-UC7, UM-UC9) and FGFR (UM-UC14, RT4, RT112,
SW780) dependent UC cell lines. CYP2J2 and GPX2 mRNA expression
was measured by quantitative PCR and normalized to UM-UC9.
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Figure 4.9 Hepatocyte-derived PPARγ gene set is enriched in FGFR3dependent cells. Gene set enrichment analyses were performed to
compare PPARγ pathway gene expression in the four FGFR3-dependent
(UM-UC14, RT4, RT112, SW780; red color coded) and the four EGFRdependent (UM-UC4, UM-UC5, UM-UC7, UM-UC9; blue color coded) cell
lines using the whole genome mRNA expression profiling data.
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PPARγ translocation to the nucleus [163,164]. Although GSEA indicated
the activation of PPARγ transcriptional pathway in FGFR dependent UC
cells that were featured constitutive expression of FABP4, it was unclear
whether PPARγ was in fact responsible for this constitutive FABP4
expression in the FGFR dependent cells because of the fact that all three
PPAR isoforms (α, β, γ) interact with similar DNA response elements
[165]. Therefore, we first used isoform-specific chemical agonists to
determine this. Exposure to the PPARγ-selective agonist rosiglitazone but
not the α- and β-isoform agonists Wy14643 and L-165,041 resulted in
strong induction of FABP4 in the EGFR-dependent cells (Figure 4.10
upper panel). We observed similar but less substantial effects in the FGFR
dependent cells, most likely because they expressed higher levels of
FABP4 at baseline (Figure 4.10 lower panel). None of the three isoformselective antagonists had any effects on FABP4 expression in the
absence of ligand (data shown for PPARγ, Figure 4.10). However, siRNA
mediated silencing of PPAR (but not the other isoforms) inhibited basal
FABP4 expression in the FGFR dependent cell lines UM-UC14 and RT4
(Figure 4.11). Taken together, these data suggested that the constitutive
high-level expression of FABP4 observed in the FGFR dependent UC
cells is caused by constitutive PPARγ activation.
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Figure 4.10 FABP4 expression is regulated by PPARγ. EGFR
dependent bladder cancer cells (UM-UC4, UM-UC5, UM-UC7, UM-UC9)
were exposed to the selective PPARγ agonist rosiglitazone and FABP4
mRNA expression was measured by quantitative RT-PCR. Modulation of
FABP4 mRNA levels by the PPARγ agonist rosiglitazone and the PPARγ
antagonist GW9662 in FGFR3 dependent bladder cancer cells (UM-UC14,
RT4).

102

A.

B.

Figure 4.11 Effects of silencing PPARα, β or γ isoform on FABP4
expression. A. Knockdown efficacy of siRNAs specific for different PPAR
isoforms. B. FABP4 expression after PPARα, β or γ knockdown. Relative
mRNA expression was measured by quantitative PCR.
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4.1.4. Modulation of FABP4 affects EGFR sensitivity
Recent publication suggests that FABP4 is an obligate co-activator for
PPARγ activation, in that FABP4 binds and delivers PPARγ ligands from
cytosol to nucleus, therefore facilitating the ligation and enhancing the
transcriptional activity of PPARγ [163,164]. Additionally, our data revealed
that FGFR dependent cells are characterized by the constitutive PPARγ
activation, whereas little/low level of PPARγ activation marks the EGFRdependent cells. Therefore, we tried to determine whether PPARγ
activation affected FGFR and/or EGFR inhibitor sensitivity. We first
exposed the EGFR dependent cell lines to rosiglitazone with or without
gefitinib and measured growth inhibition using 5-day MTT assays. We
observed that rosiglitazone alone had no effects on cell proliferation (data
not shown). However, it actually prevented the growth inhibition that was
induced by gefitinib in EGFR dependent cells (Figure 4.12). These data
appeared to contradict previous studies, which concluded that PPARγ
agonists inhibit proliferation and/or induce apoptosis in bladder cancer
cells [166,167]. However, these previous studies used very high
concentrations (≥ 100µM) of the PPARγ agonists compared to our study,
and we concluded that rosiglitazone had no effects on cell proliferation by
itself in any of the cell lines at concentrations that induced strong FABP4
expression. Furthermore, stable FABP4 knockdown (gene knockdown
efficacy shown in figure 4.13 lower panel) blocked the gefitinib resistance
induced by rosiglitazone in the EGFR dependent cell lines (UM-UC4, UM104

Figure 4.12 Activation of the PPARγ signaling pathway blocks EGFR
dependency. The EGFR-dependent UM-UC4, UM-UC5, UM-UC7, and
UM-UC9 cells were exposed to rosiglitazone (1μM), gefitinib (1μM), or a
combination of both (1μM each) at days 0 and 2, and cell proliferation was
measured at day 5 using MTT assays. Data are normalized to controls
and indicated as means ± SEM.
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Figure 4.13 Efficiency of FABP4 silencing in FGFR dependent (UMUC14 and RT4) and EGFR dependent (UM-UC5 and UM-UC9) cells.
Cells were transfected with FABP4 shRNA constructs (C6 or D4) along in
FGFR dependent cells or in the presence of absence of PPARγ agonist
rosiglitazone in the EGFR dependent cells. FABP4 mRNA expression was
measured by quantitative PCR.
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UC5, UM-UC7 and UM-UC9) (Figure 4.14). Specifically, rosiglitazone
induced resistance to gefitinib in these EGFR dependent cells (Figure
4.12). However, exposure to rosiglitazone didn’t prevent growth inhibition
induced by gefitinib when FABP4 was stably silenced (Figure 4.14).
Given that our data suggested induction of FABP4 expression promoted
resistance to gefitinib in EGFR dependent cells, it is presently unclear
whether FABP4 modulation altered sensitivity to EGFR inhibitor gefitinib in
FGFR dependent cells. Therefore, we first stably knocked down FABP4 in
FGFR dependent cell lines UM-UC14 and RT4. Gene silencing efficacy
was measured by PCR analysis (Figure 4.13 upper panel). We then
exposed the stable FABP4-knockdown UM-UC14 and RT4 with gefitinib to
test whether decreased FABP4 increased sensitivity to gefitinib. Cell
growth data revealed that FABP4 silencing induced concentration
dependent response to gefitinib in FGFR dependent cells UM-UC14 and
RT4, whereas the counterpart NT controls remained resistance to gefitinib
(Figure 4.15). Overall, we could conclude that sensitivity to EGFR inhibitor
gefitinib could be affected by PPARγ activation, specifically modulation of
FABP4.
4.1.5. CHOP acts downstream of PPARγ (Preliminary data)
To identify the downstream transcriptional targets of PPARγ that
controlled EGFR dependency, we performed whole genome gene
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Figure 4.14 FABP4 silencing blocks rosiglitazone-induced gefitinib
resistance. EGFR dependent cells (UM-UC4, UM-UC5, UM-UC7, and
UM-UC9) were stably transduced with the FABP4-specific or non-targeting
shRNA constructs. Cells were then exposed to rosiglitazone (1μM),
gefitinib (1μM), or a combination of both (1μM each) for 5 days, and cell
proliferation was measured using MTT assays. Data were normalized to
NT controls and indicated as mean ± SEM.
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Figure 4.15 Down-regulation of FABP4 promotes gefitinib sensitivity
in FGFR-dependent cells. UM-UC14 and RT4 were stably transduced
with two different FGFR3-specific lentiviral shRNA constructs (C6 or D4)
or a non-targeting (NT) control. Cells were then exposed to the indicated
concentrations of either AZD4547 or gefitinib, and cell proliferation was
measured after 48 hours using thymidine incorporation assays. Data were
normalized to NT control and indicated as mean ± SEM.
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expression profiling of the EGFR dependent UM-UC9 cells incubated with
or without rosiglitazone (in triplicate). We also performed the gene
expression profiling of the FGFR dependent UM-UC14 cells transduced
with non-targeting or FABP4-specific shRNA constructs (in triplicate). We
then performed class comparison analyses using BRB Array Tools to
extract the significantly differentially expressed genes in each cell line
group (p<0.001 with FDR <0.1) and subjected the genes to Ingenuity
Pathway Analyses (IPA). These analyses identified the known PPARγ
target FABP4 as one of top 5 activated genes in the rosiglitazone-treated
UM-UC9 cells and one of top 5 suppressed genes in the FABP4 silenced
UM-UC14 cells, which was expected and served as a positive control.
Other than FABP4, the endoplasmic reticular (ER) stress-responsive
transcription factor GADD153/CHOP (DDIT3) was the only other gene that
was shared among the top 5 altered genes in both models (Table 4.1).
Furthermore, using the IPA Upstream Regulators function, the CHOP
pathway was identified as the one that was most strongly down-regulated
in the FABP4 silenced UM-UC14 cells and most strongly up-regulated
pathway in the rosiglitazone-treated UM-UC9 cells. In addition, 4 out of 4
CHOP targeted molecules defined by IPA changed in the same direction
as CHOP did in FABP4 silenced UM-UC14 cells (Figure 16 left panel).
Among these 4 genes, GADD34, ERO1L also changed in the same
direction as CHOP did in rosiglitazone-treated UM-UC9 cells (Figure 16
right panel). Interestingly, the cyclic AMP-dependent transcription factor
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Table 4.1 Identification of GADD153/CHOP/DDIT3 as a PPARγ target
gene. List of differentially expressed genes that were shared in FABP4
knockdown UM-UC14 cells compared to non-targeting (NT) controls, and
rosiglitazone-treated UM-UC9 cells versus controls.
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UM-UC9ROSI 3

UM-UC9ROSI 2

UM-UC9ROSI 1

UM-UC9CON 3

UM-UC9CON 2

UM-UC9CON 1

UM-UC14FABP4KD 2

UM-UC14FABP4KD 1

UM-UC14NT 3

UM-UC14NT 2

UM-UC14NT 1

UM-UC14FABP4KD 3

DDIT3

ERO1L

GADD34

DDIT3

ERO1L

GADD34

CASP4

LCN2

LCN2
-2.00
-1.33
-0.67
0.00
0.67
1.33
2.00

-2.00
-1.33
-0.67
0.00
0.67
1.33
2.00

CASP4

Figure 4.16 Identification of GADD153/CHOP/DDIT3 as a PPARγ
target gene. Heatmap depicts CHOP (DDIT3) expression and expression
of its IPA-defined downstream targets (HSPE1, CASP4, ERO1L,
GADD34, LCN2) in the UM-UC14 and UM-UC9 experimental sets.
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ATF-3 (ATF3), which acts downstream of CHOP, was also among the top
IPA “upstream regulators” as measured by log ratio change in both
subsets (data not shown).

4.2. Discussion
Previous work has revealed the existence of subsets of human bladder
cancer cells that are either EGFR [115,147] or FGFR3 [70,156] dependent
for cell proliferation and tumor growth. However, little is known regarding
the underlying mechanism of such EGFR or FGFR3 dependency in
human urothelial cancer cells. Although recent studies have provided
some indirect explanation, including pathway redundancy and impaired
negative feedback loops [132], much is left to be discovered. In this study,
we directly demonstrated for the first time that EGFR and FGFR3
dependency are non-overlapping and mutually exclusive in human
urothelial cancer. Furthermore, our data suggested that this mutually
exclusive EGFR or FGFR3 dependency is tightly regulated by PPARγ
signaling both in human urothelial cancer cells and in orthotopic xenograft.
PPARγ, a member of peroxisome proliferator activated receptors active in
nucleus, is a intracellular transcription factor well known for its important
role in adipogenesis and tissue differentiation [168-171]. On the other
hand, CHOP is also a transcription factor that is extensively studied for its
role in the response to ER stress [172]. Although their roles in controlling
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of growth factor receptor dependency in human cancer have not been
reported, previously a few studies have demonstrated that C/EBP protein
family acts as co-activators with PPARγ to promote the transcription of
genes involved in adipogenesis and adiopocyte differentiation
[169,171,173]. A recent chromatin immunoprecipitaiton sequencing study
revealed that C/EBP binding motifs were located in the vicinity of PPAR
binding site, and both C/EBP proteins and PPARγ binding to specific DNA
motifs were required for robust adipocyte gene expression. Collectively,
our data suggested for the first time that PPARγ potentially coordinate with
CHOP to control EGFR dependency. To verify this hypothesis that CHOP
acts downstream of PPARγ to regulate EGFR sensitivity, we are planning
to directly silence CHOP in UM-UC14 and RT4 and test whether silencing
of CHOP sensitize these cells to EGFR antagonist gefitinib. Moreover, we
also planning to overexpress CHOP in original EGFR dependent cells
(UM-UC4, UM-UC5, UM-UC7 and UM-UC9) and test whether activation of
PPARγ by overexpression of CHOP will block the sensitivity to EGFR
inhibitor gefitinib. If our hypothesis is tested to be true, we are going to
further investigate whether PPARγ-CHOP signaling regulate EGFR
dependency through mechanisms that directly interact with the receptor.
Previous work suggested that pathway redundancy provided escape
mechanisms for acquired resistance to EGFR TKIs [132,145], which
indicated a direct interaction between EGFR and FGFR on the receptor
level. Furthermore, given the high level of downstream signal transduction
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redundancy between EGFR and FGFR3 signaling [115,156], it is possible
that PPARγ signaling employs mechanisms that directly interact with the
respective receptors rather than with downstream signaling components to
modulate EGFR or FGFR3 dependency. MIG6, one of the four EGFR
inducible feedback inhibitors, is a cytosolic protein that is induced through
EGFR activation and attenuates EGFR signaling following its activation
[174]. MIG6 contains a centrally located ErbB binding region (ERB) that
allows for specific binding to EGFR kinase domain to lock EGFR
molecules in a catalytically inactive configuration, which prevents signal
generation and transduction [174]. Moreover, MIG6 also has the capability
to rapidly down-regulate EGFR molecules and route them to lysosome for
degradation [175,176]. Overexpression of MIG6 is sufficient to abrogate
EGFR phosphorylation and activation, EGFR mediated downstream
signaling transduction, and EGFR regulated biological and cellular
function [174,177]. Given that, we are planning to directly test the
hypothesis that MIG6 (ERRFI1 or RALT) acts as a downstream target of
PPARγ signaling to inhibit EGFR dependency though MIG6’s direct
interaction between MIG6 and respective receptors without interfering with
the downstream MAPK/Erk and PI3K pathways, which are also used to
mediate FGFR3 dependency.
While our data revealed that PPARγ-CHOP signaling modulated EGFR
dependency, it is still unclear whether PPARγ-CHOP controls FGFR3
dependency. Therefore, we are planning to examine the linkage between
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PPARγ-CHOP and FGFR3 dependency. Although preliminary data
suggested that rosiglitazone alone did not increase sensitivity to the FGFR
inhibitor AZD4547 in EGFR dependent cell line UM-UC9 (data not shown),
it was possible that FGFR3 dependency required high level expression of
surface FGFR3, which was evidenced by our previous study [70,156].
Hence, we are going to direct test this hypothesis using exogenous
expression of FGFR3 in UM-UC9. Moreover, we are also planning to
examine whether PPARγ-CHOP controls FGFR3 dependency in cells
natively responding to FGFR3 inhibitors.
FGFR substrate 2α (FRS2) is a docking/scaffolding adaptor protein that
functions downstream of certain receptor tyrosine kinases to promote
signal transduction [178]. Specifically, emerging evidence indicated that
FRS2α acts as a control center for FGFR intracellular signaling. It
becomes tyrosine phosphorylation on several residues followed by FGFR
activation, which creates binding sites for SH2 domain of Grb2 adaptor
protein. The activated Grb2 recruits multiple adaptor proteins including
SOS that finally leads to strong activation of Ras/MAPK/Erk pathway
[179]. Interestingly and more importantly, FRS2α selectively binds some
receptor tyrosine kinases over the others, which is one of the unique
characters of this adaptor protein [178]. A good example is that It acts
downstream of FGFRs but not EGFR. Therefore, we could further
hypothesize that PPARγ-CHOP signaling controls FGFR3 dependency via
the induction of FRS2α without interfering with EGFR-mediated signaling,
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and we are going to test it using exogenous expression of CHOP in UMUC9 cells. Furthermore, exploring the link between PPARγ-CHOP and
FRS2α would provide direct mechanistic explanation as to why PPARγCHOP regulates FGFR3 dependency.
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CHAPTER 5. FINAL CONCLUSIONS AND FUTURE
DIRECTIONS
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5.1. Final conclusions
5.1.1. FGFR3 regulates human urothelial cancer growth
In summary, we have demonstrated that the levels of FGFR3 expression
correlate with FGFR3 dependency, and that FGFR3 is more important
than FGFR1 in driving proliferation in human urothelial cancer cells.
Specifically, FGFR3 expression correlated well with the sensitivity to the
FGFR antagonist (BGJ-398) in a panel of 17 urothelial cancer cell lines.
Furthermore, silencing of FGFR3 simulates the effects of BGJ-398
exposure in both UM-UC14 and RT4 cells in vitro. Additionally, both
exposure to BGJ-398 and FGFR3 specific knockdown using an RNAi
based strategy produced cell cycle arrest, which indicate that FGFR
inhibitors induce cytostatic but not cytotoxic in human bladder cancer
cells. Our data together with other recent studies [102,154,156] support
the ongoing development of FGFR specific inhibitors for clinical targeted
therapy, particularly in combination with chemotherapy or radiation
therapy due to their cytostatic effects. However, human urothelial cancer
cells display a remarkable heterogeneity in sensitivity to FGFR inhibitors
as revealed both in this study and previous work [156]. It is still unclear
what mechanisms drive the intrinsic sensitivity to FGFR inhibitors, though
several mechanisms have been proposed including FGFR3 activating
mutations, the presence of TACC3-FGFR3 translocation, and high level of
FGFR3 expression. The predictive value of these markers must now be
determined in urothelial cancer patients so that it is practically possible to
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identify the appropriate subset of bladder cancer patients who could
benefit markedly from the FGFR targeted therapy. Therefore, tremendous
efforts from clinical research are needed in the future to uncover the
mechanisms that could lead to successful development of biomarkers to
identify the patient population for FGFR3 targeted therapy.
5.1.2. FGFR1 mediates human urothelial cancer metastasis
More importantly, our study indicates that FGFR1 mediates cell invasion
and tumor metastasis in human urothelial cancer. Specifically, FGFR1
repression by either FGFR antagonist (BGJ-398) or direct FGFR1
silencing severely reduced cell invasion in vitro. In addition, exposure to
BGJ-398 inhibited metastasis and circulating tumor cells production
without affecting primary tumor growth in orthotopic tumor xenografts.
Consistent with our conclusion, a recent study also supports the role of
FGFR1 in promoting epithelial-to-mesenchymal transition, which results in
increased levels of invasion and metastasis [104]. Although the same
study suggested that FGFR1 promotes cell migration and invasion through
cyclooxygenase-2 (COX-2) activation, much more is left to be determined.
Further investigation utilizing global gene expression profiling and pathway
analysis would be performed to address the cause-effect questions of
what signaling pathways and transcriptional factors acting downstream of
FGFR1 to promote cell invasion and tumor metastasis. Furthermore, our
study also provides a rationale for targeting FGFR, specifically FGFR1, to
prevent invasion and treat metastasis. Clinically, ~20% of the non-muscle
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invasive bladder cancers progress to become muscle invasive and
metastatic, which accounts for the bulk of patient mortality. If appropriate
biomarkers could be developed to identify the right patient subset, FGFR1
targeted therapy combined with conventional chemotherapy could be
beneficial to this sub-group of patients. Therefore, future effects should
focus on the development of clinically relevant biomarkers to prospectively
identify patients who are more likely to benefit from FGFR targeted
therapy as well as testing the efficacy of FGFR targeted therapy in a
metastatic setting.
5.1.3. Heterogeneous sensitivity to FGFR antagonist in “epithelial”
bladder cells
Finally, our study suggests that there is profound heterogeneity of FGFR3
dependency. Specifically, although some of the urothelial cell lines that
contain activating mutations were highly sensitive to FGFR inhibitors, the
majority of FGFR3-mutant cell lines remained resistant to FGFR inhibitor
(BGJ-398). Previously, several studies have uncovered the mechanisms
how FGFR3 activating mutations drive proliferation in human bladder
cancer cells. However, our data suggest the existence of more
complicated biological interaction that urothelial cells possess, which
require further investigate to elucidate and validate. Recently, several
studies highlight the EGFR and FGFR interaction as one of the
mechanisms that cells escape from the pressure of FGFR antagonist,
which provide a direction to elucidate the mechanism of intrinsic and
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acquired resistance. We plan to further investigate the FGFR3-mutant cell
lines that are resistant to FGFR inhibitor to uncover the escape
mechanisms, with hopes of identifying the best strategies to appropriately
utilize FGFR targeted therapy to benefit patient clinically.
5.1.4. Discrete EGFR dependency is controlled by PPARγ-FABP4
transcriptional complex
We demonstrate for the first time that EGFR and FGFR3 dependency are
non-overlapping and mutually exclusive to each other in human urothelial
cancer. More specifically, we have identified 4 cell lines (UM-UC4, UMUC5, UM-UC7 and UM-UC9) that were sensitive to EGFR antagonist
gefitinib but not to FGFR antagonist AZD4547 at the clinical relevant
concentration (≤ 1μM). We also identify different 4 cell lines (UM-UC14,
SW780, RT4 and RT112) that were sensitive to FGFR inhibitor AZD4547
but not to EGFR inhibitor gefitinib. Our data indicated the possibility that
human urothelial cancer cells depends primarily on one single growth
factor receptor for growth and proliferation. However, this idea needs
extensive research to test and validate.
Furthermore, the observation that PPARγ signaling pathway controls this
mutually exclusive biological phenotype extends our knowledge of
molecular mechanism that mediates EGFR dependent proliferation. More
specifically, PPARγ signal activation is enriched in FGFR3 dependent (but
EGFR inhibitor resistant) urothelial cells, whereas EGFR dependent (but
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FGFR inhibitor resistant) urothelilal cells lack PPARγ activation. In
addition, up-regulation of FABP4 forces EGFR dependent cells becoming
resistance to EGFR antagonist while down-regulation of FABP4 promotes
sensitivity to EGFR inhibitor in FGFR3 dependent cells. Overall, we for the
first time have shown that PPARγ activation, specifically via FABP4,
represses EGFR dependency that is exclusive to FGFR3 dependency in
urothelilal cancer.

5.2. Future directions
5.2.1. FGFR1 and cell invasion
In this study, we have demonstrated that FGFR1 inhibition blocks cell
invasion and tumor metastasis. More specifically, direct FGFR1 silencing
decreased cell invasion in vitro, and the FGFR antagonist BGJ-398
reduced tumor metastasis in orthotopic UM-UC3 metastatic xenografts in
vivo. However, these interesting findings present at least two important
avenues that require further research and elucidation. First, our data
suggests that FGFR1 but not FGFR3 is responsible for cell invasion in
“mesenchymal” UM-UC3 and UM-UC13 cells. However, our in vivo data
don’t necessarily show that FGFR1 but not FGFR -2 or -3 regulated tumor
metastasis because we used BGJ-398, a pan FGFR1-3 antagonist,
instead of a direct FGFR1 inhibitor to conduct the animal study. Given the
similarity of protein sequence among FGFRs, it is very difficult to develop
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a specific FGFR1 antagonist. However, we could resolve this problem
using FGFR1 gene silencing. Specifically, we could conduct a three arm in
vivo study to directly test the hypothesis, with one arm for wild-type
metastatic UM-UC3, the second arm transduced with non-targeting
scramble shRNA, and the third arm transduced with FGFR1 specific
shRNA.
Secondly, our study and a recent publication [104] suggest the role of
FGFR1 in cell invasion and possible epithelial-to-mesenchymal transition.
However, it is presently unclear that how FGFR1 regulates cell invasion,
what molecules act downstream of FGFR1 pathway to mediate cell
invasion and whether such a regulation involves EMT. To address these
questions, we could start with gene expression profiling study to identify
differential expressed genes by directly comparing the expression profile
between non-targeting and FGFR1 knockdown in UM-UC3 and UM-UC13.
Following upon the identification of differential expressed genes, we could
use Ingenuity Pathway Analysis to dissect differential expressed genes to
pinpoints candidates for further investigation. Finally, we could test the
hypothesis that the candidate genes acts downstream of FGFR1 and are
directly responsible for cell invasion and/or epithelial-to-mesenchymal
transition.
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5.2.2. Discrete EGFR dependency and PPARγ-FABP4 axis
In this study, we have identified the non-overlapping and mutually
exclusive FGFR3 and EGFR dependency in urothelial cancer cells. The
observation prompts us to propose the hypothesis that urothelial cancer
cells or even cancer cells in genenral depends primarily on one single
growth factor receptor for cell proliferation and tumor growth [180].
Therefore, we are going to evaluate various TKIs in vitro for their effects
on proliferation of human urothelial cancer cells with the purpose to
identify cell lines that are dependent on one primary growth factor receptor
other than pre-defined EGFR and FGFR3 dependent cells in this study.
The proposed study would elucidate the tendency whether one primary
growth factor receptor drives proliferation in given cancer cells, which
would pave the way to investigate and develop molecular signatures that
would be ultimately used in clinic to improve personalized medicine.
Furthermore, it will be helpful to investigate the molecular mechanism of
such a dependency in order to identify relevant biomarkers/signatures for
clinical translation. Given that the downstream signal transduction
pathways controlled by the growth factor receptors are highly redundant, it
is more likely that the molecular signatures that are responsible for such
dependency lie in genes mediating growth factor receptor internalization,
cytoplasmic trafficking, or controlling negative feedback loop mechanism.
We plan to utilize genomic wide gene expression profiling to directly test
these hypotheses. Presently, multiple studies have suggested the role of
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pathway redundancy as one of the mechanisms cells employing to escape
from TKIs. With this context in mind, we are going to directly examine the
hypothesis that activating alternative growth factor receptors contributes to
the resistance to FGFR or EGFR inhibition, which could help us to
understand the mechanisms of intrinsic or acquired resistance.
Additionally, we demonstrate that the PPARγ signaling regulates the
EGFR dependency. These important findings present at least two
opportunities upon further experimental examination and validation.
Firstly, we have established throughout our study that PPARγ signaling
promotes CHOP expression in EGFR dependent urothelial cancer cells.
However, our data does not provide details with respect to how PPARγ
interacts with FABP4 to stimulate CHOP expression. Previously, FABP4
was shown to function as a specific co-activator for PPARγ through “ligand
tunneling”, which facilitates PPARγ ligands transferring and binding to
PPARγ receptor, and then promotes PPARγ translocation to nucleus. To
specific address this question, we plan to investigate the PPARγ-FABP4
protein to protein interaction in FGFR3 dependent cells, examine the
CHOP promoter area to identify potential PPARγ binding sites, and design
chromatin immunoprecipitation (ChIP) experiment to confirm the binding of
PPARγ-FABP4 complex to CHOP promoter.
Secondly, we identified several potential signatures, including high level of
FGFR3 expression, FGFR3 activating mutation, and activation of PPARγ
signaling, in the FGFR3 dependent cells although we haven’t established
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the cause-effect link between PPARγ activation and FGFR3 dependency.
We would further investigate this hypothesis by testing whether
modulation of PPARγ activation affects FGFR3 dependency. Furthermore,
if the hypothesis could be proven true, these findings could pave the way
for uncovering clinical biomarkers to prospectively identify appropriate
subset of patients who could benefit from FGFR3 targeted therapy.
However, further clinical research in a large scale is needed to verify the
correlation between FGFR and PPARγ-FABP4 signaling, and obtain the
biomarker profiling to support the prospective identification of patient
subset. We would also direct test the predictive power of these presumed
biomarkers (PPARγ, FABP4, FGFR3 and its mutation) in clinical trials that
are primarily designed to testing selective FGFR inhibitors in patients.
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